Nothing Special   »   [go: up one dir, main page]
Next Article in Journal
Effect of High Temperature Exposure and Laboratory Processing Techniques on the Diagnostic Performance of Dry Swabs for the Detection of African Swine Fever Virus
Previous Article in Journal
Challenges of BTV-Group Specific Serology Testing: No One Test Fits All
Previous Article in Special Issue
Is Autophagy a Friend or Foe in SARS-CoV-2 Infection?
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Viruses
Volume 16
Issue 12
10.3390/v16121811
viruses-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Neuropsychiatric Burden of SARS-CoV-2: A Review of Its Physiopathology, Underlying Mechanisms, and Management Strategies

by
Aliteia-Maria Pacnejer
1,2,
Anca Butuca
2,*,
Carmen Maximiliana Dobrea
2,
Anca Maria Arseniu
2,
Adina Frum
2,
Felicia Gabriela Gligor
2,
Rares Arseniu
3,
Razvan Constantin Vonica
2,
Andreea Loredana Vonica-Tincu
2,
Cristian Oancea
4,
Cristina Mogosan
5,
Ioana Rada Popa Ilie
6,
Claudiu Morgovan
2 and
Cristina Adriana Dehelean
1,7
1
Department of Toxicology, Drug Industry, Management and Legislation, Faculty of Pharmacy, “Victor Babeş” University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timişoara, Romania
2
Preclinical Department, Faculty of Medicine, “Lucian Blaga” University of Sibiu, 550169 Sibiu, Romania
3
County Emergency Clinical Hospital “Pius Brînzeu”, 300723 Timișoara, Romania
4
Department of Pulmonology, Center for Research and Innovation in Personalized Medicine of Respiratory Diseases, University of Medicine and Pharmacy “Victor Babeș”, 300041 Timișoara, Romania
5
Department of Pharmacology, Physiology and Pathophysiology, Faculty of Pharmacy, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400029 Cluj-Napoca, Romania
6
Department of Endocrinology, Faculty of Medicine, “Iuliu Haţieganu” University of Medicine and Pharmacy, 3-5 Louis Pasteur Street, 400349 Cluj-Napoca, Romania
7
Research Center for Pharmaco-Toxicological Evaluations, Faculty of Pharmacy, “Victor Babes” University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timişoara, Romania
*
Author to whom correspondence should be addressed.
Viruses 2024, 16(12), 1811; https://doi.org/10.3390/v16121811
Submission received: 30 October 2024 / Revised: 20 November 2024 / Accepted: 20 November 2024 / Published: 21 November 2024
(This article belongs to the Special Issue Emerging Concepts in SARS-CoV-2 Biology and Pathology 2.0)
Browse Figures
Figure 1
<p>Proposed pathways of neuropsychiatric manifestations in SARS-CoV-2 infection.</p> "> Figure 2
<p>The impact of the SARS-CoV-2 infection on the nervous system and the resulting injuries.</p> "> Figure 3
<p>Proposed underlying mechanisms for the neurological aspects of COVID-19 disease [<a href="#B75-viruses-16-01811" class="html-bibr">75</a>].</p> "> Figure 4
<p>Neurological manifestations of the SARS-CoV infection described in the literature. ADEM—acute disseminated encephalomyelitis; AHLE—acute hemorrhagic leukoencephalitis; MOGAD—myelin oligodendrocyte glycoprotein antibody-associated disease; PIMS-TS—pediatric inflammatory multisystem syndrome; PRES—posterior reversible encephalopathy syndrome.</p> "> Figure 5
<p>Management and diagnostic approaches for neurological sequelae in SARS-CoV-2 infection [<a href="#B224-viruses-16-01811" class="html-bibr">224</a>].</p> ">
Versions Notes

Abstract

:
The COVID-19 outbreak, caused by the SARS-CoV-2 virus, was linked to significant neurological and psychiatric manifestations. This review examines the physiopathological mechanisms underlying these neuropsychiatric outcomes and discusses current management strategies. Primarily a respiratory disease, COVID-19 frequently leads to neurological issues, including cephalalgia and migraines, loss of sensory perception, cerebrovascular accidents, and neurological impairment such as encephalopathy. Lasting neuropsychological effects have also been recorded in individuals following SARS-CoV-2 infection. These include anxiety, depression, and cognitive dysfunction, suggesting a lasting impact on mental health. The neuroinvasive potential of the virus, inflammatory responses, and the role of angiotensin-converting enzyme 2 (ACE2) in neuroinflammation are critical factors in neuropsychiatric COVID-19 manifestations. In addition, the review highlights the importance of monitoring biomarkers to assess Central Nervous System (CNS) involvement. Management strategies for these neuropsychiatric conditions include supportive therapy, antiepileptic drugs, antithrombotic therapy, and psychotropic drugs, emphasizing the need for a multidisciplinary approach. Understanding the long-term neuropsychiatric implications of COVID-19 is essential for developing effective treatment protocols and improving patient outcomes.

1. Introduction

In late 2019, several cases of an unknown form of pneumonia emerged in Wuhan, China, rapidly spreading across Asia and then all over the globe. The outbreak was ultimately confirmed to be caused by a new type of coronavirus [1,2,3]. It caused symptoms similar to those of the severe acute respiratory syndrome (SARS) in 2003, caused by severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) [4]. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virion has four structural proteins: the S (spike) glycoprotein, responsible for the spikes of the virus; the envelope (E) protein; the membrane (M) protein; and a nucleocapsid with helical symmetry (N) [5]. In vivo, SARS-CoV-2 interacts with the angiotensin-converting enzyme 2 (ACE2) via the outer membrane “S” protein. Peripheral ACE2 contributes to angiotensin II conversion, impacting blood pressure regulation, while in the central nervous system, ACE2 plays multiple roles in brain injury recovery, stress response, and memory function [6,7]. The SARS-CoV-2 genome is a single-stranded ribonucleic acid (RNA) molecule, which makes the virus more susceptible to mutation and rapid adaptation, allowing it to spread from one species to another [8,9,10,11]. The genome sequence of SARS-CoV-2 can cause the dysregulation of cytokine activity, i.e., an alteration of the immune response [11,12]. Also, several studies have shown that patients infected with SARS-CoV-2 develop hyperinflammatory syndrome associated with increased circulating cytokine levels, like TNFα and IL-6.
In February 2020, WHO named the SARS-CoV-2-induced infection as the “new Coronavirus Disease 2019” (COVID-19) [13]. Although COVID-19 is primarily classified as an acute respiratory syndrome, it may also cause dysfunction of several organs and systems, particularly the central and peripheral nervous systems, given the virus’s ability to impact multiple organs. This happens particularly in patients who develop severe forms of the disease, where an excessive inflammatory cascade can be observed, disrupting the function of vital organs (cytokine storm), with subsequent bleeding disorder, low oxygen levels, liver impairment, septicemia, and acute kidney impairment (AKI). As far as neurological manifestations are concerned, these are often seen in COVID-19 patients, and range from light and non-specific symptoms, like headache, dizziness, fatigue, myalgia, anosmia, and ageusia, to more serious events such as stroke, delirium, coma, and encephalopathy [14,15,16,17,18,19,20,21,22,23]. Further studies show that a considerable number of COVID-19 patients face persistent neuropsychiatric alterations that can lead to mood changes like depression, anxiety, post-traumatic stress disorder (PTSD), and decreased cognitive function [24,25,26,27,28].
Various neurological symptoms can represent initial signs of COVID-19 and can develop in patients with or without underlying disease [29,30,31].
The development of neurological symptoms during hospitalization in patients with severe SARS-CoV-2 infection, as well as a history of neurological conditions, are associated with a higher mortality in COVID-19 disease [32,33,34,35]. Pre-existent metabolic syndromes, older age, and a dysregulated immune response are also key risk factors for increased severity and mortality due to COVID-19 infection [23]. The neuropsychiatric effects of SARS-CoV-2, like depression and cognitive impairment, highlight the need for comprehensive care, as similar inflammatory and lifestyle-related mechanisms are seen in conditions such as ischemic heart disease. For example, inflammatory responses and stressors associated with COVID-19 disease can worsen mood disorders and cognitive function, just as depression exacerbates outcomes in ischemic heart disease patients. This parallel suggests that COVID-19 patients, especially those experiencing both neuropsychiatric and systemic symptoms, could benefit from management strategies that address both mental health and physical well-being [36,37]. However, the pathways leading to such neuropsychiatric alterations in COVID-19 and their long-term consequences are still a topic for debate among researchers [38,39,40].
Different studies suggested a higher negative impact on mental health during COVID-19 in the low- and middle-income countries compared to high-income countries. Often, poor mental health support facilities represent the main cause of the increased incidence of neurologic and psychiatric disorders (e.g., depression, anxiety, neurocognitive disorders, etc.) [41,42,43].
However, it was not only the infection that caused damage, but lockdown had a negative impact on mental health during pandemic, too. Thus, a higher number of cases of psychiatric disorders as depression, anxiety, insomnia, etc., were reported. Also, ADHD was reported more frequently in children because of school closures. Additionally, burnout was frequently reported in healthcare professionals during this pandemic [44].

2. Classification and Underlying Factors of COVID-19 Disease

Neurological and neuropsychiatric involvement has been widely reported with COVID-19 and can occur both in the acute phase of the disease and in the post-infection recovery period. According to National Institute for Health and Care Excellence (NICE), COVID-19 can be classified into three distinct phases, starting from the time of infection and the onset of symptoms:
  • acute phase of COVID-19 infection: first 4 weeks after disease onset [45,46];
  • subacute phase of COVID-19: this includes manifestations occurring between weeks 4 and 12 after the onset of the acute phase [46,47];
  • chronic phase of COVID-19: this category includes symptoms that last for more than 12 weeks after the acute phase onset, and which are not consistent with a different diagnosis [48,49].
Post-COVID-19 syndrome is an umbrella term for symptoms, signs, and conditions persisting or appearing 4 weeks after the acute phase of infection. Patients experience persistent symptomatology following the SARS-CoV-2 infection that cannot be related to any other disease [46,49]. Post-COVID-19 syndrome is a complex condition with symptoms and mechanisms that have yet to be fully understood. Some studies suggest that high levels of D-dimer, C-reactive protein, and the presence of lymphopenia may be associated with an increased susceptibility to develop post-COVID-19 symptoms [50,51,52,53]. An abundance of studies has been identified in the literature which mention neurological symptoms of post-COVID-19.
One of the most important determinants of the neurological and psychiatric outcomes in COVID-19 patients is host immunity. The direct cytopathic effects of SARS-CoV-2 can lead to significant neurological damage and dysfunction, manifesting as a range of neurological sequelae. These sequelae are often exacerbated by neuroinflammation, which contributes to neurological and psychiatric symptoms.
Another key factor is the expression of ACE2 and other receptors. Systemic inflammation and the cytokine storm induced by SARS-CoV-2 infection can cause endothelial dysfunction and vasculopathy [54]. Dysregulation of the renin–angiotensin–aldosterone system (RAAS) may also contribute to neurological manifestations. The SARS-CoV-2 virus enters host cells by binding to the S protein and ACE2. This results in endothelial inflammation, endothelial and mitochondrial dysfunction, and inactivation of endothelial nitric oxide synthetase (eNOS), the enzyme responsible for nitric oxide (NO) production [55]. This can lead to the deregulation of the renin–angiotensin and kinin–kinase systems, affecting both cardiovascular and cerebrovascular balance [56].
The endothelium dysfunction produced by SARS-CoV-2 infection can aggravate adverse events such as inflammation and microvascular thrombosis in severe cases, including pulmonary thrombosis complications [57].
Viral factors, such as mutations and variants of the SARS-CoV-2 virus, play an important role too. These factors can lead to coagulopathy and thrombosis, which are critical pathological processes underlying many neurological complications [58]. These complications include the same wide range of neurological symptoms seen in neuroinflammation and RAAS dysregulation.
Other factors include pre-existing neurodegenerative diseases, like dementia or Parkinson’s disease, where the SARS-CoV-2 infection may exacerbate the underlying disease and lead to more severe outcomes, such as cerebrovascular events, due to thrombotic microangiopathy and hypercoagulable state, and anxiety [59,60].
The main proposed pathways by which SARS-CoV-2 infection may lead to neuropsychiatric manifestations, are summarized in Figure 1.

3. Physiopathology of Neuropsychiatric Presentations Associated with COVID-19 Disease

The pathophysiology of COVID-19 involves complex interactions between oxidative stress and inflammation, with viral binding to ACE2 initiating endothelial and mitochondrial dysfunction that exacerbates the production of reactive oxygen species, further promoting a pro-inflammatory state and endothelial damage. The cytokine storm observed in severe cases of COVID-19 leads to a cascade of systemic inflammation, endotheliosis, and a prothrombotic environment, highlighting the role of oxidative stress and inflammation in the neurological and vascular complications associated with the disease [61].
The neurological alterations induced by COVID-19 disease are the result of complex pathogenic mechanisms. These include viral neuroinvasion, causing direct neuronal damage, cerebrovascular hypoxia, ischemia, increased inflammation, and increased coagulability. Typical neurological findings indicate damage to the nervous system, both central and peripheral, the most seen symptoms being dizziness, headache, hyposmia, and dysgeusia. Figure 2 presents the impact of the SARS-CoV-2 infection on the nervous system and its associated manifestations.

3.1. Experimental Studies

Animal studies have provided valuable insights into the mechanisms by which SARS-CoV-2 may affect the CNS and contribute to neurological symptoms. Experiments on mice, particularly those genetically modified to overexpress ACE2 receptors, allow researchers to observe the virus’s ability to invade the brain, disrupt the BBB, and impact various neural cells. These studies are crucial for understanding the virus’s neurotropism, the immune response within the CNS, and potential neurodegenerative effects, offering important knowledge that can complement clinical findings in human studies.
Experiments in which the SARS-CoV-2 virus was administered intranasally to ACE2 overexpressing mice were able to demonstrate the neurotropism of the virus in the brain [62]. Furthermore, the spike protein of the virus crossed the blood–brain barrier (BBB) and reached the parenchyma by adsorptive transcytosis, a vesicle-dependent transport mechanism [63]. Also, microglia have been found to play a role in the process of synapse elimination that leads to memory deficits following a viral infection [64,65].

3.2. Clinical Studies

The literature describes various pathways for SARS-CoV-2 penetration into the Central Nervous System (CNS), in particular, retrograde transport through peripheral nerves and viruses entering the brain through the olfactory pathway that supposed the invasion of the virus in the nasal neuroepithelium, the olfactory bulb, and its cortical projections [66,67,68,69]. After its binding by the olfactory nerve terminals, the virus is internalized by endocytosis. Then, it is transported to different brain regions through the circulatory system crossing the blood–brain barrier (BBB) [70,71].
This can be achieved either through the endothelial cells, through the migration of infected leukocytes, or by reaching the cerebrospinal fluid (CSF) through the epithelial cells of the choroid plexus [70].
Experiments in which SARS-CoV-2 was administered intranasally to ACE2 overexpressing mice were able to demonstrate the neurotropism of the virus in the brain [62]. In mice, the spike protein of the virus crossed the blood–brain barrier (BBB) and reached the parenchyma by adsorptive transcytosis, a vesicle-dependent transport mechanism (Figure 3) [63].
Certain studies suggest that SARS-CoV-2 may be responsible for infecting neurons as well as astrocytes, therefore leading to neurodegeneration. Furthermore, extensive protein expression and infectious viral fragments were found in SARS-CoV-2-infected neutrospheres and brain organoids. This suggests that SARS-CoV-2 can not only infect these cells, but also replicate within them, potentially leading to cell death and loss of synapses in neurons. Most studies in the literature also indicate that brain infiltration by the SARS-CoV-2 virus or its viral proteins might, potentially, cause neurological deficits in infected individuals, although it is known that coronaviruses are not primarily neurotropic viruses [25,62,72,73,74].
Viruses 16 01811 g003
Figure 3. Proposed underlying mechanisms for the neurological aspects of COVID-19 disease [75].
Figure 3. Proposed underlying mechanisms for the neurological aspects of COVID-19 disease [75].
Viruses 16 01811 g003
Viral infections of the brain can cause temporary or long-term neurological or psychiatric dysfunction, like anxiety or depression, and motor deficits. Furthermore, inflammation in the brain and an abnormal inflammatory response can disrupt neuron function and cause long-term deficits, resulting in impaired synapses and memory [64,65,76,77].
Microglia cells are a type of glial cell found throughout the brain, spinal cord, the retina, and the olfactory bulb. They serve as the primary and most crucial line of active immune defense in the CNS and are essential for normal CNS function, during both development and response to injury. They also regulate different inflammation responses, including repair, cytotoxicity, regeneration, and immunosuppression, through different activation states or phenotypes [78,79,80,81,82].
In the context of neurodegeneration, microglia are involved in both protective and potentially harmful processes because they can release proinflammatory cytokines, which can contribute to the progression of neurodegenerative disease, but they can also help to clear neuronal debris and damaged neurons, which is beneficial. Dysregulation of microglial function has been implicated in several neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis [76,77,79,83]. Also, the process called “microglia priming” is the process by which microglial cells change their morphology and become a primary source of inflammatory cytokines [84]. It is known that microglia and macrophages express ACE2 but most blood immune cells do not, suggesting other receptors like toll-like receptors (TLRs) may be involved in the inflammatory response in COVID-19 disease [85,86,87].
Another type of glial cell that contributes to the development of neurological injury and age-related cognitive decline is the astrocytes, which have been shown to be incredibly diverse in their functions. This heterogeneity means that astrocytes play different roles in brain health and pathology, and their functions may change as the brain ages [88]. Astrocytes are involved in processes such as supporting neuronal function, contributing to the integrity of the BBB, regulating blood flow, neurotransmitter regulation, neuronal repair and scarring, and are responsible for producing neurotrophic factors and anti-inflammatory cytokines, like interleukin (IL)-10 [89,90,91,92]. On the other hand, reactive astrocytes are astrocytes that morphologically, molecularly, and functionally remodel in response to CNS injury or infection, when certain proinflammatory factors are released in the microglia, specifically complement component 1q (C1q), IL-1α and tumor necrosis factor alpha (TNFα). These factors elicit the functional change of astrocytes into A1 reactive astrocytes, which are harmful and release a toxic factor which kills neurons and oligodendrocytes. This remodeling has been known for over a century, but there is still uncertainty and controversy regarding the role of reactive astrocytes in CNS disorders, recovery, and senescence [93,94,95,96,97,98,99,100].
SARS-CoV-2 infection has been shown in several brain autopsy studies to be responsible for a local inflammatory response, microglial activation, signs of hypoxia, cerebral infarcts, and infection of astrocytes, which may lead to impaired neuronal viability and therefore explain some of the neurological symptoms associated with COVID-19, such as fatigue, depression, and “brain fog” [25,62,101,102,103,104]. Astrocyte activation, along with increased levels of biomarkers of CNS injury such as neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP) and total tau protein, were also observed in the CSF of patients with COVID-19 and were correlated with disease severity and duration of intensive care [105,106,107,108].
The CNS has unique immune responses compared to peripheral tissues due to its specialized structure and function and the BBB plays a crucial role in shaping these responses [109]. As a response to the infection, proinflammatory cytokines are released and several studies suggest that TNFα, IL-1β, and IL-6 are significantly increased during infections and can cause learning and memory impairments. Also, TNF and IL-1β are incriminated to disrupt the BBB, while IL-1β is linked to the degeneration of dopaminergic neurons and cognitive impairments, highlighting the role of inflammation in neurodegenerative processes [109,110,111].
However, cytokines like interferon-gamma (IFN-γ) and IL-4 play an essential role in maintaining normal cognitive and social behaviors. Disruptions in the balance of these cytokines during infections can lead to behavioral alterations and neuropsychiatric symptoms [112,113,114].
One of the most important proinflammatory cytokines involved in mediating the inflammatory response within the CNS are TNFα and IL-6 [115,116,117]. TNFα acts through two separate surface receptors (TNF-R 1 and TNF-R 2) and is responsible for the cellular stress response mechanism [115,118]. Central upregulation of TNFα has been linked to dopaminergic neuron death, cognitive dysfunction, memory impairment, and disruption of the BBB, facilitating the entry of leukocytes into the CNS [64,117,119].
In brain homeostasis, IL-6 is present in low concentrations, but during CNS infection elevated IL-6 levels are responsible for memory and cognitive impairment [120,121]. In SARS-CoV-2 infection, IL-6 and TNFα are linked to disease progression and severity, prompting research into treatments targeting these cytokines [122,123]. Some findings suggest that IL-6 can be a crucial biomarker for monitoring and potentially predicting the progression of severe COVID-19 pneumonia [124,125,126]. The effects of key cytokines, including TNFα, IL-1β, IL-6, IFN-γ, and IFN-α, on neurotransmitter pathways and neuronal activity during SARS-CoV-2 infection are summarized in Supplementary Materials—Table S1 [127,128,129,130,131,132,133,134,135,136].

4. Inflammatory Response, Cognitive Impairment and Neuropsychiatric Manifestations Associated with COVID-19 Disease

In 2020, the first retrospective analysis was conducted on 214 patients in Wuhan, which found that 36.4% of patients exhibited neurological symptoms [137]. These symptoms were classified into CNS, peripheral nervous system, and skeletal muscle injuries.
Neurological manifestations have been reported in around 80% of patients hospitalized with COVID-19 [138], and patients with severe COVID-19 are at a higher risk of developing neurological complications, although the specific underlying mechanisms remain unclear [16].
Psychiatric disorders such as schizophrenia augmented the risk of COVID-19 infection and mortality, the risk of severe infections increasing during exposure to antipsychotic drugs [139]. Moreover, schizophrenia could be one of the post-COVID-19 sequelae. Thus, Baranova et al. suggested that the risk of schizophrenia was increased by 11% in severe COVID-19 patients [140]. Also, different studies showed that patients with ADHD have an increased risk of infection and of the severe COVID-19 symptoms [141,142].
Although in patients with autism, the long COVID-19 symptoms are difficult to diagnose and manage [143]; aberrant behaviors of autistic patients are related to their mother’s anxiety level. Thus, a worsening of the behavior was correlated with a high level of anxiety in the patients’ mothers [144].
Other retrospective studies reported that one in three COVID-19 survivors were diagnosed with a neuropsychiatric condition within six months of infection, with 13% of them being first-time diagnoses [28,145].
In an observational study of 43 patients infected with SARS-CoV-2, Paterson et al. described the main neurological symptoms of COVID-19 disease: encephalopathy, which is sometimes linked to episodes of delirium and psychosis; CNS inflammatory syndromes such as acute disseminated encephalomyelitis (ADEMs); parainfectious and postinfectious encephalitis; myelitis; ischemic stroke commonly complicated by pulmonary thromboembolic events, and Guillain-Barré syndrome (GBS) [146].
An Italian study reported that 78% of COVID-19 survivors had cognitive deficits, and 36% experienced depressive symptoms linked to inflammation [26]. The inflammatory response is a common factor in neurodegenerative conditions and mood disorders such as major depressive disorder, where stress can exacerbate inflammation. The most frequent neurological symptoms determined by the SARS-CoV infection described in the literature are represented in Figure 4.
Some studies in the literature reported that COVID-19 patients with neurological disorders show anti-SARS-CoV-2 antibodies in the CSF [23,147,148]. For example, immunoglobulin-G (IgG) antibodies were present in the CSF of all patients with encephalopathy [148], while another study showed a low prevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients [149].
The role of BBB selectivity is to protect the brain from circulating blood cells and to maintain CNS homeostasis. Systemic infection and inflammation can alter the permeability of the barrier, allowing cytokines and inflammatory mediators to enter the CNS, promoting neuroinflammation and neurodegeneration [150].
Some post mortem assays of COVID-19 patients have found undetectable or extremely low concentrations of SARS-CoV-2 RNA in their CSF [63,151,152,153,154,155]. In addition, abnormalities on brain magnetic resonance imaging (MRI), in particular leptomeningeal enhancement, and increased inflammatory markers CSF, are common in COVID-19 patients with neurological symptoms [156]. Jarius et al. found dysfunction of the BBB in 50% of patients with no history of CNS disease [157].
Exposure to the SARS-CoV-2 spike glycoprotein S1 in microglia, mononuclear blood cells, and macrophages triggers the production of proinflammatory cytokines, such as TNFα, IL-8, IL-1β, and IL-6 [158,159,160]. Furthermore, treatment with a TLR4 antagonist in murine macrophages attenuated the proinflammatory cytokine induction and intracellular signaling activation by S1, suggesting that TLR4 signaling appears to play a crucial role in inducing inflammatory responses, including neuroinflammation [159,161,162,163,164]. Other studies suggest that the “S” protein activates the nuclear factor kappa-B (NF-κB) pathway via TLR2 in a MyD88-dependent manner. This pathway plays a crucial role in the cytokine storm observed during COVID-19 [165,166].

5. Acute Neuropsychiatric Complications of COVID-19

In terms of severe acute COVID-19 complications, these comprise ischemic or hemorrhagic stroke, hypoxic-anoxic injuries, PRES, and acute disseminated myelitis, as well as the occurrence of neuromuscular disorders, such as GBS, which can lead to persistent or even permanent neurological impairment [138]. A study examining the medical records of more than 40,000 COVID-19 patients revealed that 22.5% had neurological and/or psychiatric complaints, of which anxiety and related disorders were the most common [167].
There are also reports in the literature of psychotic episodes in patients during the acute phase of COVID-19. One study found that the most common neuropsychiatric syndrome was early psychosis, followed by other associated psychiatric disorders [168,169]. In a Spanish cohort of COVID-19 inpatients, approximately 20% presented neuropsychiatric symptoms, including insomnia, anxiety, depression, and psychosis [17]. Case reports have also documented the presence of manic and psychotic symptoms in patients with COVID-19 who had no prior psychiatric diagnosis [170,171].
The most frequently reported acute symptoms of COVID-19 in the literature, together with the possible associated pathophysiology, are presented in Table 1.

6. Chronic Neuropsychiatric Symptoms and Post-Recovery

There are several neurological and psychiatric diseases known to be mediated by a neuroinflammatory process, like the one described for COVID-19. The molecular mechanisms causing this inflammation may have a considerable impact on the development and progression of neurodegenerative diseases, but also of psychiatric disorders, especially mood disorders, as their pathogenesis also involves neuroinflammatory mechanisms. Research to date has associated increased levels of C-reactive protein with the incidence of cognitive deficits post-infection in patients who have recovered. This would suggest a possible role of inflammation in the cognitive deficit reported by this group of post-recovery patients [195]. Maamar et al. found that patients who had elevated serum levels of inflammatory markers, such as C-reactive protein, neutrophil-to-lymphocyte ratio, neutrophils, and fibrinogen exhibited prolonged COVID-19 symptoms [196].
According to the National Academies of Sciences, Engineering, and Medicine in 2024, long COVID-19, also known as post-acute sequelae of SARS-CoV-2 infection, is defined broadly as signs, symptoms, and conditions that continue or develop after the initial phase of COVID-19 infection. These manifestations persist for four weeks or more, can be multisystemic, and may exhibit a relapsing-remitting pattern with potential for progression or worsening over time. This term encompasses various health issues that might have different biological causes and risk factors and unfortunately, there are currently no consensus-based diagnostic criteria for long COVID-19 [197].
Although evidence for a causal link between COVID-19-associated neuroinflammation and the onset of psychiatric disorders remains limited, it is nevertheless possible that this category of patients with neuroinflammatory impairment may be more likely to develop depression, anxiety, and long-term PTSD [198,199,200].
One can also hypothesize about the long-term CNS effects of COVID-19 based on the physiopathological mechanisms implicated in the development of long-term neuropsychiatric disorders associated with SARS-CoV-1 and Middle East respiratory syndrome (MERS). A study of SARS-CoV-1 survivors showed that 55% of them experienced PTSD, 39% developed depression, over 32% experienced panic disorder, and 15.6% exhibited an obsessive-compulsive disorder [201].
Mood disorders, mainly depression, are also more common in post-infection COVID-19 patients than in those recovering from influenza or other respiratory tract infections [28].
In patients with long COVID-19 syndrome, including those who have not been hospitalized, at least one persistent neuropsychiatric symptom has been reported [202].
In 2022, about 6.9% of adults and 1.3% of children in the U.S. experienced long COVID-19 at some point. By January 2023, the prevalence among U.S. adults was recorded at 5.9%, which increased to 6.8% by January 2024, demonstrating a continuing and significant burden of the disease. Although the overall prevalence has decreased since mid-2022, long COVID-19 still presents a substantial health burden. Approximately 22% of adults with long COVID-19 reported significant activity limitations as of January 2024 [197]. The most frequent long COVID-19 symptoms reported in the literature are presented in Table 2 [197].
A retrospective cohort study was conducted in 1,284,437 COVID-19 patients over two years. The study found that after six months, most patients still faced a significantly increased risk of neurological damage. Additionally, there were but a few conditions, such as encephalitis, GBS, nerve and plexus damage, and Parkinson’s disease that did not show an increased incidence among COVID-19 patients. At the same time, the incidence of cognitive deficits, dementia, psychiatric disorders, epilepsy, and seizures was still high even after two years. Children were at greater risk of developing cognitive deficiencies, insomnia, intracranial hemorrhage, ischemic stroke, nervous disorders, epilepsy, or seizures, while adults were more likely to develop common psychiatric disorders [203]. As multiple studies have shown, the symptoms of COVID-19 infection in children are less severe than in the adult population. Also, older age is associated with an increased risk of long-term symptoms [204]. Another characteristic of the pediatric population is that patients with multisystem inflammatory syndrome (MIS) have a higher prevalence of long COVID, including neurologic and psychiatric symptoms, compared to patients without MIS [205]. Over a longer follow-up period, neurological and psychiatric symptoms due to long COVID were observed to decrease. Symptoms due to long COVID in children seem to be reversible, even though in some cases it may take a long time [205].

7. Diagnosis of COVID-19 Neuropsychiatric Manifestations and Biomarkers Used to Monitor Neurological and Psychiatric Alterations in COVID-19 Patients

Clinical assessment is an important step in diagnosing neuropsychiatric symptoms in patients with COVID-19 disease. This involves a series of laboratory tests needed to rule out other diagnoses such as metabolic disorders, CNS infections, and psychiatric disorders.
If the symptoms are consistent with focal neurological deficits, or if there is a suspicion that they may be associated with COVID-19 disease, a brain MRI is strongly recommended.
As for the diagnostic criteria for mood disorders such as major depressive disorder and anxiety disorders in COVID-19 patients, they do not differ from the standard criteria used in their diagnosis.

7.1. Biomarkers

Monitoring neurological and psychiatric changes in patients with COVID-19 requires a complex approach that includes clinical assessment, neuroimaging, and evaluation of specific biomarkers associated with CNS dysfunction and psychological distress. Biomarkers play an important role in establishing the diagnosis, but also in predicting disease severity.
Multiple studies have examined serum biomarkers in order to evaluate the nature of CNS injury. Plasma NfL (pNfL), an intra-axial structural protein, is a validated biomarker for detecting neuro-axial injury, while plasma GFAP (pGFAP) is an astrocytic cytoskeletal protein that is overexpressed in activated astrocytes [206,207,208,209]. Both markers, including also other CSF biomarkers and ubiquitin C-terminal hydrolase L1 (UCH-L1), have been shown to be elevated in the acute phase of SARS-CoV-2 infection, suggesting that CNS damage is linked to neuronal impairment and astrocyte activation during acute infection [105,210,211,212,213,214].
Furthermore, additional studies in the literature support the relation between GFAP levels and the development of severe disease in COVID-19 patients. GFAP is a glial cytoskeletal protein mainly expressed in astrocytes, which regulates the morphology and function of these cells in the CNS [215,216,217]. Serum levels of GFAP in healthy patients are very low, but in case of neuronal injury, GFAP levels increase [99,216]. To date, there are no specific biomarkers for the SARS-CoV-2 infection. However, several biomarkers are commonly used to assess the severity of COVID-19, the inflammatory response and potential complications. The most common non-specific biomarkers, used to monitor neurological and psychiatric impairment in COVID-19 disease and that are described in the literature, are listed in Table 3.

7.2. Imagistic Investigations

Together with specific biomarkers, neuroimaging plays an important role in observing microstructural changes with implications for cognitive function and neuro-psychiatric outcomes. Thus, in COVID-19 patients with neurological manifestations, neuroimaging could detect underlying causal pathology.
Neuroimaging helps specialists to observe the microstructural changes in cognitive function and neurological outcomes in COVID-19 patients. Thus, different neuroimaging techniques dominated by MRI, computed tomography (CT), and positron emission tomography (PET) could be used in evaluating the abnormalities attributable to hypoxic, vascular, and inflammatory pathology. Advanced neuroimaging revealed cerebral abnormalities of olfactory system, cortical hypoperfusion, BBB leakage, white matter microstructural integrity alterations, altered glucose metabolism in the COVID-19 brain, acute ischemic stroke, cerebral venous thrombosis, and meningoencephalitis. [30,218,219,220].

7.3. Psychological Tools

Different tools were used for the evaluation of the mental status of the patients with COVID-19 such as:
  • COVID-19 Stress Scale for understanding the distress associated with COVID-19 and for identifying people in need of mental health services. Based on 36 items, the scale identifies 5 factors: (1) danger, (2) fears about economic consequences, (3) xenophobia, (4) compulsive checking and reassurance seeking, and (5) traumatic stress symptoms about COVID-19.
  • Depression, Stress and Anxiety Scale 21, a self-report questionnaire based on 21 questions,
  • Generalized Anxiety Disorder-7 questionnaire for evaluation of the generalized anxiety symptoms during the 2 weeks (based on the Likert Scale),
  • The COVID-19 Peritraumatic Distress Index contains 24 items regarding the anxiety, depression, specific phobias, cognitive change, avoidant and compulsive behaviors, physical symptoms and loss of social functioning in the past week (based on the Likert Scale) [221,222].

8. Pharmacotherapy of Neuropsychiatric Disorders and Management Strategies Associated with COVID-19

The primary treatment for most neuropsychiatric events associated with COVID-19 is supportive therapy. A multidisciplinary approach is essential to effectively manage the comorbidities of COVID-19 patients.
A retrospective UK study of 184,986 adult hospitalized patients revealed that patients cotreated with dexamethasone and remdesivir experienced fewer neurological events such as strokes, seizures, encephalitis, or meningitis compared with those receiving standard treatment [223].
Also, in patients with severe COVID-19 who received either dexamethasone or remdesivir or their combination, a reduction in neurological manifestations was observed.
The effects of other drugs on reducing neurological impairment, such as tocilizumab, ritonavir, baricitinib, or nirmatrelvir, which have been effective in treating SARS-CoV-2 infection, have not yet been reported. However, these drugs in turn target inflammation or viral replication and are expected to have a similar effect on neurological complications. Likewise, seizures were reduced in COVID-19 patients with severe disease who were administered either dexamethasone or remdesivir or a combination of the two. Incidence of meningitis and/or encephalitis events also decreased in the severe disease groups following dexamethasone or combination therapy, which suggests the possible benefit of reducing CNS inflammatory events.
Therefore, the management of neurological and psychiatric manifestations of COVID-19 involves a tailored approach based on specific symptoms. In patients presenting with acute neurological complications, such as encephalitis or stroke, antiepileptic drugs, antithrombotic therapy, and supportive therapy, respectively, may be indicated depending on the clinical presentation. Psychiatric symptoms, including anxiety, depression, and psychosis, may require initiation of serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), or antipsychotic drugs. However, particular attention should be paid to potential drug interactions and adverse effects, especially in patients with underlying medical conditions or who use concomitant medication [224].
However, more research is needed to corroborate this. Immunization programs have been successful in significantly decreasing the incidence and severity of COVID-19 cases. Several clinical studies performed in post-vaccination COVID-19 infections concluded that the use of the vaccine is associated with a lower risk of hypercoagulopathy or venous thromboembolism, seizures, or psychotic disorder especially after the second vaccine dose [225]. Also, a reduction in the risk of neuropsychiatric disorders involved in post-vaccinated COVID-19 patients was reported [226]. Moreover, the key finding of a recent study published in June 2024, was that the median self-reported time to recovery from SARS-CoV-2 infection was approximately 20 days, 1 in 5 COVID-19 patients had not fully recovered from the infection after 90 days, and interestingly, vaccination before the infection and infection with an Omicron variant was associated with shorter recovery times [227].
While adenovirus vaccines have been associated with a small number of neurological disorders, such as GBS, studies suggest that the risk of neurological events caused by SARS-CoV-2 infection greatly exceeds the risk following vaccination [228]. Evidence from a recent meta-analysis suggests that vaccination lowers the risk of developing post-COVID-19 disease, with patients who received two vaccine doses showing a significantly lower risk compared to those who remained unvaccinated. Nevertheless, further investigations are needed in order to improve the treatment of comorbidities associated with a severe form of COVID-19 disease and thus to reduce the risk of neurological complications [229].
Figure 5 describes the management and diagnostic approaches for the key neurological sequelae in SARS-CoV-2 infection (Supplementary Materials—Table S2) [230].

9. Conclusions

The SARS-CoV-2 virus has a profound impact beyond its primary respiratory manifestations, significantly affecting the central and peripheral nervous systems. This review highlights the wide range of neurological and psychiatric symptoms associated with COVID-19, from mild conditions such as headache and anosmia to severe complications such as stroke and encephalopathy. Long-term neuropsychiatric disorders, including cognitive dysfunction, anxiety, and depression, highlight the long-term consequences of SARS-CoV-2 infection.
Understanding the underlying mechanisms of these neuropsychiatric manifestations is critical. Key factors include the ability of the virus to invade the CNS, the resulting inflammatory response and the role of ACE2 receptors in neuroinflammation. The review also highlights the importance of specific biomarkers in diagnosing and monitoring CNS involvement, which can guide treatment strategies.
Effective management of the neurological and psychiatric effects of COVID-19 requires a multidisciplinary approach combining supportive care with targeted pharmacological treatments. Further research into these mechanisms and management strategies is essential to improve patient outcomes and address the long-term mental health effects of COVID-19. Neuropsyciatric implications must be considered when developing health strategies. Not at least, further studies would be helpful to fill the gap regarding the developing of the neuropsychiatric symptoms in different populations, or regarding the neuropsychiatric outcomes in vaccinated or non-vaccinated population compared to other viral infections.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/v16121811/s1, Table S1: The effects of cytokines on neurotransmitter pathways and neuronal activity; Table S2: Therapeutic management of COVID-19 disease, according to NICE guidelines, version May 2024.

Author Contributions

Conceptualization, A.-M.P., A.B., F.G.G., C.M. (Cristina Mogosan) and C.A.D.; methodology, A.-M.P., A.B., A.F., C.M.D., A.M.A., A.L.V.-T., C.M. (Claudiu Morgovan) and C.A.D.; software, A.-M.P., R.A., A.F., C.M.D., R.C.V., I.R.P.I. and C.M. (Claudiu Morgovan); validation, C.O., F.G.G., C.M. (Cristina Mogosan), I.R.P.I. and C.A.D.; formal analysis, A.-M.P., A.B., A.M.A., A.F. and A.L.V.-T.; investigation, A.-M.P., A.B., A.F., C.M.D., R.A., R.C.V. and L.V; resources, A.-M.P., A.B., F.G.G. and C.A.D.; data curation, C.M.D., A.F., C.M (Claudiu Morgovan)., R.A., I.R.P.I., A.L.V.-T., C.M. (Cristina Mogosan) and C.A.D.; writing—original draft preparation, A.-M.P., A.B., C.M.D., A.F., A.M.A., R.A. and R.C.V. writing—review and editing, A.L.V.-T., C.O., F.G.G., C.M. (Cristina Mogosan), C.M. (Claudiu Morgovan) and C.A.D.; visualization, A.-M.P., A.B., C.M.D., A.M.A., A.F., F.G.G., R.A., R.C.V., A.L.V.-T., C.O., C.M. (Cristina Mogosan), I.R.P.I., C.M. (Claudiu Morgovan) and C.A.D.; supervision, C.O., F.G.G., C.M. (Cristina Mogosan) and C.A.D.; project administration, A.-M.P., A.B. and C.A.D.; funding acquisition, A.-M.P., A.B. and C.A.D. All authors have read and agreed to the published version of the manuscript.

Funding

The project financed by Lucian Blaga University of Sibiu through the research grant LBUS-IRG-2023/No. 3523, 24 July 2023.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data contained within the article.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

ACE2angiotensin-converting enzyme 2
ADEMacute disseminated encephalomyelitis
AHLEacute hemorrhagic leukoencephalitis
AKIacute kidney injury
BBBblood-brain barrier
BDNFbrain-derived neurotrophic factor
BPblood pressure
B12vitamin B12
C1qcomplement component 1q
CNScentral nervous system
COVID-19Coronavirus Disease 2019
CRPC-reactive protein
CSFcerebrospinal fluid
CTcomputed tomography
CXRchest X-Ray
EEGelectroencephalogram
EMGelectromyography
eNOSendothelial nitric oxide synthetase
ESRerythrocyte sedimentation rate
FBCfull blood count
GBSGuillain-Barré syndrome
GFAPglial fibrillary acidic protein
HbA1Chemoglobin A1c
IgGimmunoglobulin G
ICUintensive care unit
IFN-γinterferon-gamma
ILinterleukin
LFTsliver function tests
MERSMiddle East Respiratory syndrome
MISmultisystem inflammatory syndrome
MOGADmyelin oligodendrocyte glycoprotein antibody-associated disease
MRImagnetic resonance imaging
NCSnerve conduction studies
NfLneurofilament light chain
NICENational Institute for Health and Care Excellence
NOnitric oxide
OPopening pressure
PCRpolymerase chain reaction
pGFAPplasma glial fibrillary acidic protein
PIMS-TSpediatric inflammatory multisystem syndrome
pNfLplasma neurofilament light chain
PRESposterior reversible encephalopathy syndrome
PTSDpost-traumatic stress disorder
RAASrenin-angiotensin-aldosterone system
RNAribonucleic acid
SARSsevere acute respiratory syndrome
SARS-CoV-1severe acute respiratory syndrome coronavirus 1
SARS-CoV-2severe acute respiratory syndrome coronavirus 2
SNRIserotonin-norepinephrine reuptake inhibitors
SSRIselective serotonin reuptake inhibitors
TFTsthyroid function tests
TLRtoll-like receptor
TNFαtumor necrosis factor-alpha
UCH-L1Ubiquitin C-Terminal Hydrolase L1
U&Esurea and electrolytes
WCCwhite cell count
WHOWorld Health Organization

References

  1. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733. [Google Scholar] [CrossRef] [PubMed]
  2. Knutsen Glette, M.; Ludlow, K.; Wiig, S.; Bates, D.W.; Austin, E.E. Resilience Perspective on Healthcare Professionals’ Adaptations to Changes and Challenges Resulting from the COVID-19 Pandemic: A Meta-Synthesis. BMJ Open 2023, 13, e071828. [Google Scholar] [CrossRef] [PubMed]
  3. Ghibu, S.; Juncan, A.M.; Rus, L.L.; Frum, A.; Dobrea, C.M.; Chiş, A.A.; Gligor, F.G.; Morgovan, C. The Particularities of Pharmaceutical Care in Improving Public Health Service during the COVID-19 Pandemic. Int. J. Environ. Res. Public Health 2021, 18, 9776. [Google Scholar] [CrossRef]
  4. Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; et al. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature 2020, 579, 270–273. [Google Scholar] [CrossRef]
  5. Mariano, G.; Farthing, R.J.; Lale-Farjat, S.L.M.; Bergeron, J.R.C. Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. Front. Mol. Biosci. 2020, 7, 605236. [Google Scholar] [CrossRef]
  6. Alenina, N.; Bader, M. ACE2 in Brain Physiology and Pathophysiology: Evidence from Transgenic Animal Models. Neurochem. Res. 2019, 44, 1323–1329. [Google Scholar] [CrossRef]
  7. Zhao, Y.; Zhao, Z.; Wang, Y.; Zhou, Y.; Ma, Y.; Zuo, W. Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2. Am. J. Respir. Crit. Care Med. 2020, 202, 756–759. [Google Scholar] [CrossRef]
  8. Lorente-González, M.; Suarez-Ortiz, M.; Landete, P. Evolution and Clinical Trend of SARS-CoV-2 Variants. Open Respir. Arch. 2022, 4, 100169. [Google Scholar] [CrossRef] [PubMed]
  9. Emrani, J.; Ahmed, M.; Jeffers-Francis, L.; Teleha, J.C.; Mowa, N.; Newman, R.H.; Thomas, M.D. SARS-CoV-2, Infection, Transmission, Transcription, Translation, Proteins, and Treatment: A Review. Int. J. Biol. Macromol. 2021, 193, 1249–1273. [Google Scholar] [CrossRef]
  10. Fehr, A.R.; Perlman, S. Coronaviruses: An Overview of Their Replication and Pathogenesis. In Coronaviruses: Methods and Protocols; Humana Press: New York, NY, USA, 2015. [Google Scholar]
  11. Machhi, J.; Herskovitz, J.; Senan, A.M.; Dutta, D.; Nath, B.; Oleynikov, M.D.; Blomberg, W.R.; Meigs, D.D.; Hasan, M.; Patel, M.; et al. The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. J. Neuroimmune Pharmacol. 2020, 15, 359–386. [Google Scholar] [CrossRef]
  12. Gu, J.; Korteweg, C. Pathology and Pathogenesis of Severe Acute Respiratory Syndrome. Am. J. Pathol. 2007, 170, 1136–1147. [Google Scholar] [CrossRef]
  13. World Health Organization. WHO COVID-19 Dashboard. Available online: https://data.who.int/dashboards/covid19/ (accessed on 4 June 2024).
  14. Chen, T.; Wu, D.; Chen, H.; Yan, W.; Yang, D.; Chen, G.; Ma, K.; Xu, D.; Yu, H.; Wang, H.; et al. Clinical Characteristics of 113 Deceased Patients with Coronavirus Disease 2019: Retrospective Study. BMJ 2020, 368, m1091. [Google Scholar] [CrossRef]
  15. Wadman, M.; Couzin-Frankel, J.; Kaiser, J.; Matacic, C. How Does Coronavirus Kill? Clinicians Trace a Ferocious Rampage through the Body, from Brain to Toes. Science (1979) 2020. [Google Scholar] [CrossRef]
  16. Mao, L.; Jin, H.; Wang, M.; Hu, Y.; Chen, S.; He, Q.; Chang, J.; Hong, C.; Zhou, Y.; Wang, D.; et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020, 77, 683–690. [Google Scholar] [CrossRef]
  17. Romero-Sánchez, C.M.; Díaz-Maroto, I.; Fernández-Díaz, E.; Sánchez-Larsen, Á.; Layos-Romero, A.; García-García, J.; González, E.; Redondo-Peñas, I.; Perona-Moratalla, A.B.; Del Valle-Pérez, J.A.; et al. Neurologic Manifestations in Hospitalized Patients with COVID-19: The ALBACOVID Registry. Neurology 2020, 95, E1060–E1070. [Google Scholar] [CrossRef]
  18. Helms, J.; Kremer, S.; Merdji, H.; Clere-Jehl, R.; Schenck, M.; Kummerlen, C.; Collange, O.; Boulay, C.; Fafi-Kremer, S.; Ohana, M.; et al. Neurologic Features in Severe SARS-CoV-2 Infection. N. Engl. J. Med. 2020, 382, 2268–2270. [Google Scholar] [CrossRef] [PubMed]
  19. Lechien, J.R.; Chiesa-Estomba, C.M.; De Siati, D.R.; Horoi, M.; Le Bon, S.D.; Rodriguez, A.; Dequanter, D.; Blecic, S.; El Afia, F.; Distinguin, L.; et al. Olfactory and Gustatory Dysfunctions as a Clinical Presentation of Mild-to-Moderate Forms of the Coronavirus Disease (COVID-19): A Multicenter European Study. Eur. Arch. Oto-Rhino-Laryngol. 2020, 277, 2251–2261. [Google Scholar] [CrossRef]
  20. Oxley, T.J.; Mocco, J.; Majidi, S.; Kellner, C.P.; Shoirah, H.; Singh, I.P.; De Leacy, R.A.; Shigematsu, T.; Ladner, T.R.; Yaeger, K.A.; et al. Large-Vessel Stroke as a Presenting Feature of COVID-19 in the Young. N. Engl. J. Med. 2020, 382, e60. [Google Scholar] [CrossRef]
  21. Poyraz, B.Ç.; Poyraz, C.A.; Olgun, Y.; Gürel, Ö.; Alkan, S.; Özdemir, Y.E.; Balkan, İ.İ.; Karaali, R. Psychiatric Morbidity and Protracted Symptoms after COVID-19. Psychiatry Res. 2021, 295, 113604. [Google Scholar] [CrossRef]
  22. Benussi, A.; Pilotto, A.; Premi, E.; Libri, I.; Giunta, M.; Agosti, C.; Alberici, A.; Baldelli, E.; Benini, M.; Bonacina, S.; et al. Clinical Characteristics and Outcomes of Inpatients with Neurologic Disease and COVID-19 in Brescia, Lombardy, Italy. Neurology 2020, 95, e910–e920. [Google Scholar] [CrossRef]
  23. Lyra e Silva, N.M.; Barros-Aragão, F.G.Q.; De Felice, F.G.; Ferreira, S.T. Inflammation at the Crossroads of COVID-19, Cognitive Deficits and Depression. Neuropharmacology 2022, 209, 109023. [Google Scholar] [CrossRef]
  24. Nath, A. Long-Haul COVID. Neurology 2020, 95, 559–560. [Google Scholar] [CrossRef]
  25. Crunfli, F.; Carregari, V.C.; Veras, F.P.; Silva, L.S.; Nogueira, M.H.; Antunes, A.S.L.M.; Vendramini, P.H.; Valença, A.G.F.; Brandão-Teles, C.; Zuccoli, G.d.S.; et al. Morphological, Cellular, and Molecular Basis of Brain Infection in COVID-19 Patients. Proc. Natl. Acad. Sci. USA 2022, 119, e2200960119. [Google Scholar] [CrossRef]
  26. Mazza, M.G.; Palladini, M.; De Lorenzo, R.; Magnaghi, C.; Poletti, S.; Furlan, R.; Ciceri, F.; Rovere-Querini, P.; Benedetti, F. Persistent Psychopathology and Neurocognitive Impairment in COVID-19 Survivors: Effect of Inflammatory Biomarkers at Three-Month Follow-Up. Brain Behav. Immun. 2021, 94, 138–147. [Google Scholar] [CrossRef]
  27. Taquet, M.; Luciano, S.; Geddes, J.R.; Harrison, P.J. Bidirectional Associations between COVID-19 and Psychiatric Disorder: Retrospective Cohort Studies of 62 354 COVID-19 Cases in the USA. Lancet Psychiatry 2021, 8, 130–140. [Google Scholar] [CrossRef]
  28. Taquet, M.; Geddes, J.R.; Husain, M.; Luciano, S.; Harrison, P.J. 6-Month Neurological and Psychiatric Outcomes in 236 379 Survivors of COVID-19: A Retrospective Cohort Study Using Electronic Health Records. Lancet Psychiatry 2021, 8, 416–427. [Google Scholar] [CrossRef]
  29. Mohamed, A.; Qureshi, A.S.; Mohamed, S.A. Neurological Manifestations of COVID-19 in Absence of Respiratory Symptoms or Fever. Cureus 2021, 13, e13887. [Google Scholar] [CrossRef]
  30. Molaverdi, G.; Kamal, Z.; Safavi, M.; Shafiee, A.; Mozhgani, S.-H.; Ghobadi, M.Z.; Goudarzvand, M. Neurological Complications after COVID-19: A Narrative Review. eNeurologicalSci 2023, 33, 100485. [Google Scholar] [CrossRef]
  31. Nurmukanova, V.; Matsvay, A.; Gordukova, M.; Shipulin, G. Square the Circle: Diversity of Viral Pathogens Causing Neuro-Infectious Diseases. Viruses 2024, 16, 787. [Google Scholar] [CrossRef]
  32. Chou, S.H.-Y.; Beghi, E.; Helbok, R.; Moro, E.; Sampson, J.; Altamirano, V.; Mainali, S.; Bassetti, C.; Suarez, J.I.; McNett, M.; et al. Global Incidence of Neurological Manifestations Among Patients Hospitalized with COVID-19—A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. JAMA Netw. Open 2021, 4, e2112131. [Google Scholar] [CrossRef]
  33. Tahira, A.C.; Verjovski-Almeida, S.; Ferreira, S.T. Dementia Is an Age-independent Risk Factor for Severity and Death in COVID-19 Inpatients. Alzheimer’s Dement. 2021, 17, 1818–1831. [Google Scholar] [CrossRef]
  34. Romagnolo, A.; Balestrino, R.; Imbalzano, G.; Ciccone, G.; Riccardini, F.; Artusi, C.A.; Bozzali, M.; Ferrero, B.; Montalenti, E.; Montanaro, E.; et al. Neurological Comorbidity and Severity of COVID-19. J. Neurol. 2021, 268, 762–769. [Google Scholar] [CrossRef]
  35. Nemani, K.; Li, C.; Olfson, M.; Blessing, E.M.; Razavian, N.; Chen, J.; Petkova, E.; Goff, D.C. Association of Psychiatric Disorders with Mortality Among Patients with COVID-19. JAMA Psychiatry 2021, 78, 380. [Google Scholar] [CrossRef]
  36. Bondar, L.I.; Osser, B.; Osser, G.; Mariș, M.A.; Piroș, L.E.; Almășan, R.; Toth, C.; Miuta, C.C.; Marconi, G.R.; Bouroș-Tataru, A.-L.; et al. The Connection Between Depression and Ischemic Heart Disease: Analyzing Demographic Characteristics, Risk Factors, Symptoms, and Treatment Approaches to Identify Their Relationship. Clin. Pract. 2024, 14, 2166–2186. [Google Scholar] [CrossRef]
  37. Bondar, L.I.; Osser, B.; Osser, G.; Mariș, M.A.; Piroș, E.L.; Almășan, R.; Popescu, M.I. Ischemic Heart Disease as an Important Risk Factor for Depression—A Case Report. Appl. Sci. 2024, 14, 1969. [Google Scholar] [CrossRef]
  38. Webb, B.J.; Peltan, I.D.; Jensen, P.; Hoda, D.; Hunter, B.; Silver, A.; Starr, N.; Buckel, W.; Grisel, N.; Hummel, E.; et al. Clinical Criteria for COVID-19-Associated Hyperinflammatory Syndrome: A Cohort Study. Lancet Rheumatol. 2020, 2, e754–e763. [Google Scholar] [CrossRef]
  39. Lucas, C.; Wong, P.; Klein, J.; Castro, T.B.R.; Silva, J.; Sundaram, M.; Ellingson, M.K.; Mao, T.; Oh, J.E.; Israelow, B.; et al. Longitudinal Analyses Reveal Immunological Misfiring in Severe COVID-19. Nature 2020, 584, 463–469. [Google Scholar] [CrossRef]
  40. Tay, M.Z.; Poh, C.M.; Rénia, L.; MacAry, P.A.; Ng, L.F.P. The Trinity of COVID-19: Immunity, Inflammation and Intervention. Nat. Rev. Immunol. 2020, 20, 363–374. [Google Scholar] [CrossRef]
  41. Aksunger, N.; Vernot, C.; Littman, R.; Voors, M.; Meriggi, N.F.; Abajobir, A.; Beber, B.; Dai, K.; Egger, D.; Islam, A.; et al. COVID-19 and Mental Health in 8 Low- and Middle-Income Countries: A Prospective Cohort Study. PLoS Med. 2023, 20, e1004081. [Google Scholar] [CrossRef]
  42. Castro-de-Araujo, L.F.S.; Machado, D.B. Impact of COVID-19 on Mental Health in a Low and Middle-Income Country. Cien Saude Colet. 2020, 25, 2457–2460. [Google Scholar] [CrossRef]
  43. Borges-Machado, F.; Barros, D.; Ribeiro, Ó.; Carvalho, J. The Effects of COVID-19 Home Confinement in Dementia Care: Physical and Cognitive Decline, Severe Neuropsychiatric Symptoms and Increased Caregiving Burden. Am. J. Alzheimers Dis. Other Demen 2020, 35, 1533317520976720. [Google Scholar] [CrossRef] [PubMed]
  44. Ferwana, I.; Varshney, L.R. The Impact of COVID-19 Lockdowns on Mental Health Patient Populations in the United States. Sci. Rep. 2024, 14, 5689. [Google Scholar] [CrossRef]
  45. Wynberg, E.; van Willigen, H.D.G.; Dijkstra, M.; Boyd, A.; Kootstra, N.A.; van den Aardweg, J.G.; van Gils, M.J.; Matser, A.; de Wit, M.R.; Leenstra, T.; et al. Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset. Clin. Infect. Dis. 2022, 75, e482–e490. [Google Scholar] [CrossRef]
  46. Dutta, A.; Mitra, S.; Mitra, D. A Preliminary Survey of the Postacute Symptoms of COVID-19 among Hospital-Discharged Patients and a Proposed Quantitative Framework for Assessment. J. Health Allied Sci. NU 2023, 13, 090–097. [Google Scholar] [CrossRef]
  47. Nalbandian, A.; Sehgal, K.; Gupta, A.; Madhavan, M.V.; McGroder, C.; Stevens, J.S.; Cook, J.R.; Nordvig, A.S.; Shalev, D.; Sehrawat, T.S.; et al. Post-Acute COVID-19 Syndrome. Nat. Med. 2021, 27, 601–615. [Google Scholar] [CrossRef] [PubMed]
  48. Greenhalgh, T.; Knight, M.; A’Court, C.; Buxton, M.; Husain, L. Management of Post-Acute COVID-19 in Primary Care. BMJ 2020, 370, m3026. [Google Scholar] [CrossRef]
  49. Shah, W.; Hillman, T.; Playford, E.D.; Hishmeh, L. Managing the Long Term Effects of COVID-19: Summary of NICE, SIGN, and RCGP Rapid Guideline. BMJ 2021, 372, n136. [Google Scholar] [CrossRef]
  50. Townsend, L.; Fogarty, H.; Dyer, A.; Martin-Loeches, I.; Bannan, C.; Nadarajan, P.; Bergin, C.; O’Farrelly, C.; Conlon, N.; Bourke, N.M.; et al. Prolonged Elevation of D-dimer Levels in Convalescent COVID-19 Patients Is Independent of the Acute Phase Response. J. Thromb. Haemost. 2021, 19, 1064–1070. [Google Scholar] [CrossRef]
  51. Yong, S.J. Long COVID or Post-COVID-19 Syndrome: Putative Pathophysiology, Risk Factors, and Treatments. Infect. Dis. 2021, 53, 737–754. [Google Scholar] [CrossRef]
  52. Lai, Y.-J.; Liu, S.-H.; Manachevakul, S.; Lee, T.-A.; Kuo, C.-T.; Bello, D. Biomarkers in Long COVID-19: A Systematic Review. Front. Med. 2023, 10, 1085988. [Google Scholar] [CrossRef]
  53. Liu, F.; Li, L.; Xu, M.; Wu, J.; Luo, D.; Zhu, Y.; Li, B.; Song, X.; Zhou, X. Prognostic Value of Interleukin-6, C-Reactive Protein, and Procalcitonin in Patients with COVID-19. J. Clin. Virol. 2020, 127, 104370. [Google Scholar] [CrossRef]
  54. Cooper, S.L.; Boyle, E.; Jefferson, S.R.; Heslop, C.R.A.; Mohan, P.; Mohanraj, G.G.J.; Sidow, H.A.; Tan, R.C.P.; Hill, S.J.; Woolard, J. Role of the Renin–Angiotensin–Aldosterone and Kinin–Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID. Int. J. Mol. Sci. 2021, 22, 8255. [Google Scholar] [CrossRef]
  55. Lei, Y.; Zhang, J.; Schiavon, C.R.; He, M.; Chen, L.; Shen, H.; Zhang, Y.; Yin, Q.; Cho, Y.; Andrade, L.; et al. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circ. Res. 2021, 128, 1323–1326. [Google Scholar] [CrossRef]
  56. Bernard, I.; Limonta, D.; Mahal, L.; Hobman, T. Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19. Viruses 2020, 13, 29. [Google Scholar] [CrossRef] [PubMed]
  57. Magro, C.; Mulvey, J.J.; Berlin, D.; Nuovo, G.; Salvatore, S.; Harp, J.; Baxter-Stoltzfus, A.; Laurence, J. Complement Associated Microvascular Injury and Thrombosis in the Pathogenesis of Severe COVID-19 Infection: A Report of Five Cases. Transl. Res. 2020, 220, 1–13. [Google Scholar] [CrossRef]
  58. Tang, N.; Bai, H.; Chen, X.; Gong, J.; Li, D.; Sun, Z. Anticoagulant Treatment Is Associated with Decreased Mortality in Severe Coronavirus Disease 2019 Patients with Coagulopathy. J. Thromb. Haemost. 2020, 18, 1094–1099. [Google Scholar] [CrossRef]
  59. Sluis, W.M.; Linschoten, M.; Buijs, J.E.; Biesbroek, J.M.; den Hertog, H.M.; Ribbers, T.; Nieuwkamp, D.J.; van Houwelingen, R.C.; Dias, A.; van Uden, I.W.M.; et al. Risk, Clinical Course, and Outcome of Ischemic Stroke in Patients Hospitalized with COVID-19: A Multicenter Cohort Study. Stroke 2021, 52, 3978–3986. [Google Scholar] [CrossRef]
  60. Suzuki, K.; Numao, A.; Komagamine, T.; Haruyama, Y.; Kawasaki, A.; Funakoshi, K.; Fujita, H.; Suzuki, S.; Okamura, M.; Shiina, T.; et al. Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Parkinson’s Disease and Their Caregivers: A Single-Center Survey in Tochigi Prefecture. J. Park. Dis. 2021, 11, 1047–1056. [Google Scholar] [CrossRef]
  61. Rochette, L.; Ghibu, S. Mechanics Insights of Alpha-Lipoic Acid Against Cardiovascular Diseases During COVID-19 Infection. Int. J. Mol. Sci. 2021, 22, 7979. [Google Scholar] [CrossRef] [PubMed]
  62. Song, E.; Zhang, C.; Israelow, B.; Lu-Culligan, A.; Prado, A.V.; Skriabine, S.; Lu, P.; Weizman, O.-E.; Liu, F.; Dai, Y.; et al. Neuroinvasion of SARS-CoV-2 in Human and Mouse Brain. J. Exp. Med. 2021, 218, e20202135. [Google Scholar] [CrossRef] [PubMed]
  63. Rhea, E.M.; Logsdon, A.F.; Hansen, K.M.; Williams, L.M.; Reed, M.J.; Baumann, K.K.; Holden, S.J.; Raber, J.; Banks, W.A.; Erickson, M.A. The S1 Protein of SARS-CoV-2 Crosses the Blood–Brain Barrier in Mice. Nat. Neurosci. 2021, 24, 368–378. [Google Scholar] [CrossRef]
  64. Figueiredo, C.P.; Barros-Aragão, F.G.Q.; Neris, R.L.S.; Frost, P.S.; Soares, C.; Souza, I.N.O.; Zeidler, J.D.; Zamberlan, D.C.; de Sousa, V.L.; Souza, A.S.; et al. Zika Virus Replicates in Adult Human Brain Tissue and Impairs Synapses and Memory in Mice. Nat. Commun. 2019, 10, 3890. [Google Scholar] [CrossRef]
  65. Vasek, M.J.; Garber, C.; Dorsey, D.; Durrant, D.M.; Bollman, B.; Soung, A.; Yu, J.; Perez-Torres, C.; Frouin, A.; Wilton, D.K.; et al. A Complement–Microglial Axis Drives Synapse Loss during Virus-Induced Memory Impairment. Nature 2016, 534, 538–543. [Google Scholar] [CrossRef]
  66. Desforges, M.; Le Coupanec, A.; Dubeau, P.; Bourgouin, A.; Lajoie, L.; Dubé, M.; Talbot, P.J. Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Viruses 2019, 12, 14. [Google Scholar] [CrossRef]
  67. Meinhardt, J.; Radke, J.; Dittmayer, C.; Franz, J.; Thomas, C.; Mothes, R.; Laue, M.; Schneider, J.; Brünink, S.; Greuel, S.; et al. Olfactory Transmucosal SARS-CoV-2 Invasion as a Port of Central Nervous System Entry in Individuals with COVID-19. Nat. Neurosci. 2021, 24, 168–175. [Google Scholar] [CrossRef]
  68. Cooper, K.W.; Brann, D.H.; Farruggia, M.C.; Bhutani, S.; Pellegrino, R.; Tsukahara, T.; Weinreb, C.; Joseph, P.V.; Larson, E.D.; Parma, V.; et al. COVID-19 and the Chemical Senses: Supporting Players Take Center Stage. Neuron 2020, 107, 219–233. [Google Scholar] [CrossRef]
  69. Joyce, J.D.; Moore, G.A.; Goswami, P.; Harrell, T.L.; Taylor, T.M.; Hawks, S.A.; Green, J.C.; Jia, M.; Irwin, M.D.; Leslie, E.; et al. SARS-CoV-2 Rapidly Infects Peripheral Sensory and Autonomic Neurons, Contributing to Central Nervous System Neuroinvasion before Viremia. Int. J. Mol. Sci. 2024, 25, 8245. [Google Scholar] [CrossRef]
  70. Pezzini, A.; Padovani, A. Lifting the Mask on Neurological Manifestations of COVID-19. Nat. Rev. Neurol. 2020, 16, 636–644. [Google Scholar] [CrossRef]
  71. Haidar, M.; Shakkour, Z.; Reslan, M.; Al-Haj, N.; Chamoun, P.; Habashy, K.; Kaafarani, H.; Shahjouei, S.; Farran, S.; Shaito, A.; et al. SARS-CoV-2 Involvement in Central Nervous System Tissue Damage. Neural Regen. Res. 2022, 17, 1228. [Google Scholar] [CrossRef]
  72. Ramani, A.; Müller, L.; Ostermann, P.N.; Gabriel, E.; Abida-Islam, P.; Müller-Schiffmann, A.; Mariappan, A.; Goureau, O.; Gruell, H.; Walker, A.; et al. SARS-CoV-2 Targets Neurons of 3D Human Brain Organoids. EMBO J. 2020, 39, e106230. [Google Scholar] [CrossRef]
  73. Zhang, B.-Z.; Chu, H.; Han, S.; Shuai, H.; Deng, J.; Hu, Y.; Gong, H.; Lee, A.C.-Y.; Zou, Z.; Yau, T.; et al. SARS-CoV-2 Infects Human Neural Progenitor Cells and Brain Organoids. Cell Res. 2020, 30, 928–931. [Google Scholar] [CrossRef]
  74. Pedrosa, C.d.S.G.; Goto-Silva, L.; Temerozo, J.R.; Souza, L.R.Q.; Vitória, G.; Ornelas, I.M.; Karmirian, K.; Mendes, M.A.; Gomes, I.C.; Sacramento, C.Q.; et al. Non-Permissive SARS-CoV-2 Infection in Human Neurospheres. Stem Cell Res. 2021, 54, 102436. [Google Scholar] [CrossRef]
  75. Shehata, G.A.; Lord, K.C.; Grudzinski, M.C.; Elsayed, M.; Abdelnaby, R.; Elshabrawy, H.A. Neurological Complications of COVID-19: Underlying Mechanisms and Management. Int. J. Mol. Sci. 2021, 22, 4081. [Google Scholar] [CrossRef]
  76. Frost, P.S.; Barros-Aragão, F.; da Silva, R.T.; Venancio, A.; Matias, I.; Lyra e Silva, N.M.; Kincheski, G.C.; Pimentel-Coelho, P.M.; De Felice, F.G.; Gomes, F.C.A.; et al. Neonatal Infection Leads to Increased Susceptibility to Aβ Oligomer-Induced Brain Inflammation, Synapse Loss and Cognitive Impairment in Mice. Cell Death Dis. 2019, 10, 323. [Google Scholar] [CrossRef]
  77. De Sousa, V.L.; Araújo, S.B.; Antonio, L.M.; Silva-Queiroz, M.; Colodeti, L.C.; Soares, C.; Barros-Aragão, F.; Mota-Araujo, H.P.; Alves, V.S.; Coutinho-Silva, R.; et al. Innate Immune Memory Mediates Increased Susceptibility to Alzheimer’s Disease-like Pathology in Sepsis Surviving Mice. Brain Behav. Immun. 2021, 95, 287–298. [Google Scholar] [CrossRef] [PubMed]
  78. Lannes, N.; Eppler, E.; Etemad, S.; Yotovski, P.; Filgueira, L. Microglia at Center Stage: A Comprehensive Review about the Versatile and Unique Residential Macrophages of the Central Nervous System. Oncotarget 2017, 8, 114393–114413. [Google Scholar] [CrossRef]
  79. Hickman, S.; Izzy, S.; Sen, P.; Morsett, L.; El Khoury, J. Microglia in Neurodegeneration. Nat. Neurosci. 2018, 21, 1359–1369. [Google Scholar] [CrossRef]
  80. Muzio, L.; Viotti, A.; Martino, G. Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy. Front. Neurosci. 2021, 15, 742065. [Google Scholar] [CrossRef]
  81. Samudyata; Oliveira, A.O.; Malwade, S.; Rufino de Sousa, N.; Goparaju, S.K.; Gracias, J.; Orhan, F.; Steponaviciute, L.; Schalling, M.; Sheridan, S.D.; et al. SARS-CoV-2 Promotes Microglial Synapse Elimination in Human Brain Organoids. Mol. Psychiatry 2022, 27, 3939–3950. [Google Scholar] [CrossRef]
  82. Song, G.J.; Suk, K. Pharmacological Modulation of Functional Phenotypes of Microglia in Neurodegenerative Diseases. Front. Aging Neurosci. 2017, 9, 139. [Google Scholar] [CrossRef]
  83. Xie, D.; He, M.; Hu, X. Microglia/Macrophage Diversities in Central Nervous System Physiology and Pathology. CNS Neurosci. Ther. 2019, 25, 1287–1289. [Google Scholar] [CrossRef] [PubMed]
  84. Lima, M.N.; Barbosa-Silva, M.C.; Maron-Gutierrez, T. Microglial Priming in Infections and Its Risk to Neurodegenerative Diseases. Front. Cell Neurosci. 2022, 16, 878987. [Google Scholar] [CrossRef] [PubMed]
  85. Song, X.; Hu, W.; Yu, H.; Zhao, L.; Zhao, Y.; Zhao, X.; Xue, H.; Zhao, Y. Little to No Expression of Angiotensin-converting Enzyme-2 on Most Human Peripheral Blood Immune Cells but Highly Expressed on Tissue Macrophages. Cytom. Part. A 2023, 103, 136–145. [Google Scholar] [CrossRef] [PubMed]
  86. Verdecchia, P.; Cavallini, C.; Spanevello, A.; Angeli, F. The Pivotal Link between ACE2 Deficiency and SARS-CoV-2 Infection. Eur. J. Intern. Med. 2020, 76, 14–20. [Google Scholar] [CrossRef] [PubMed]
  87. Beyerstedt, S.; Casaro, E.B.; Rangel, É.B. COVID-19: Angiotensin-Converting Enzyme 2 (ACE2) Expression and Tissue Susceptibility to SARS-CoV-2 Infection. Eur. J. Clin. Microbiol. Infect. Dis. 2021, 40, 905–919. [Google Scholar] [CrossRef]
  88. Matias, I.; Morgado, J.; Gomes, F.C.A. Astrocyte Heterogeneity: Impact to Brain Aging and Disease. Front. Aging Neurosci. 2019, 11, 59. [Google Scholar] [CrossRef]
  89. Li, K.; Li, J.; Zheng, J.; Qin, S. Reactive Astrocytes in Neurodegenerative Diseases. Aging Dis. 2019, 10, 664. [Google Scholar] [CrossRef]
  90. Boisvert, M.M.; Erikson, G.A.; Shokhirev, M.N.; Allen, N.J. The Aging Astrocyte Transcriptome from Multiple Regions of the Mouse Brain. Cell Rep. 2018, 22, 269–285. [Google Scholar] [CrossRef]
  91. Nave, K.-A. Myelination and Support of Axonal Integrity by Glia. Nature 2010, 468, 244–252. [Google Scholar] [CrossRef]
  92. Eroglu, C.; Barres, B.A. Regulation of Synaptic Connectivity by Glia. Nature 2010, 468, 223–231. [Google Scholar] [CrossRef]
  93. Escartin, C.; Galea, E.; Lakatos, A.; O’Callaghan, J.P.; Petzold, G.C.; Serrano-Pozo, A.; Steinhäuser, C.; Volterra, A.; Carmignoto, G.; Agarwal, A.; et al. Reactive Astrocyte Nomenclature, Definitions, and Future Directions. Nat. Neurosci. 2021, 24, 312–325. [Google Scholar] [CrossRef]
  94. Hou, J.; Bi, H.; Ge, Q.; Teng, H.; Wan, G.; Yu, B.; Jiang, Q.; Gu, X. Heterogeneity Analysis of Astrocytes Following Spinal Cord Injury at Single-cell Resolution. FASEB J. 2022, 36, e22442. [Google Scholar] [CrossRef] [PubMed]
  95. Boulton, M.; Al-Rubaie, A. Neuroinflammation and Neurodegeneration Following Traumatic Brain Injuries. Anat. Sci. Int. 2024. [Google Scholar] [CrossRef]
  96. Liddelow, S.A.; Barres, B.A. Reactive Astrocytes: Production, Function, and Therapeutic Potential. Immunity 2017, 46, 957–967. [Google Scholar] [CrossRef] [PubMed]
  97. Clarke, L.E.; Liddelow, S.A.; Chakraborty, C.; Münch, A.E.; Heiman, M.; Barres, B.A. Normal Aging Induces A1-like Astrocyte Reactivity. Proc. Natl. Acad. Sci. USA 2018, 115, E1896–E1905. [Google Scholar] [CrossRef]
  98. Soung, A.; Klein, R.S. Viral Encephalitis and Neurologic Diseases: Focus on Astrocytes. Trends Mol. Med. 2018, 24, 950–962. [Google Scholar] [CrossRef]
  99. Liddelow, S.A.; Guttenplan, K.A.; Clarke, L.E.; Bennett, F.C.; Bohlen, C.J.; Schirmer, L.; Bennett, M.L.; Münch, A.E.; Chung, W.-S.; Peterson, T.C.; et al. Neurotoxic Reactive Astrocytes Are Induced by Activated Microglia. Nature 2017, 541, 481–487. [Google Scholar] [CrossRef] [PubMed]
  100. Lawrence, J.M.; Schardien, K.; Wigdahl, B.; Nonnemacher, M.R. Roles of Neuropathology-Associated Reactive Astrocytes: A Systematic Review. Acta Neuropathol. Commun. 2023, 11, 42. [Google Scholar] [CrossRef]
  101. Kong, W.; Montano, M.; Corley, M.J.; Helmy, E.; Kobayashi, H.; Kinisu, M.; Suryawanshi, R.; Luo, X.; Royer, L.A.; Roan, N.R.; et al. Neuropilin-1 Mediates SARS-CoV-2 Infection of Astrocytes in Brain Organoids, Inducing Inflammation Leading to Dysfunction and Death of Neurons. mBio 2022, 13, e02308-22. [Google Scholar] [CrossRef]
  102. Stefano, G.B.; Ptacek, R.; Ptackova, H.; Martin, A.; Kream, R.M. Selective Neuronal Mitochondrial Targeting in SARS-CoV-2 Infection Affects Cognitive Processes to Induce ‘Brain Fog’ and Results in Behavioral Changes That Favor Viral Survival. Med. Sci. Monit. 2021, 27, e930886-1. [Google Scholar] [CrossRef]
  103. Murta, V.; Villarreal, A.; Ramos, A.J. Severe Acute Respiratory Syndrome Coronavirus 2 Impact on the Central Nervous System: Are Astrocytes and Microglia Main Players or Merely Bystanders? ASN Neuro 2020, 12, 175909142095496. [Google Scholar] [CrossRef] [PubMed]
  104. Pattanaik, A.; Bhandarkar, B.S.; Lodha, L.; Marate, S. SARS-CoV-2 and the Nervous System: Current Perspectives. Arch. Virol. 2023, 168, 171. [Google Scholar] [CrossRef] [PubMed]
  105. Virhammar, J.; Nääs, A.; Fällmar, D.; Cunningham, J.L.; Klang, A.; Ashton, N.J.; Jackmann, S.; Westman, G.; Frithiof, R.; Blennow, K.; et al. Biomarkers for Central Nervous System Injury in Cerebrospinal Fluid Are Elevated in COVID-19 and Associated with Neurological Symptoms and Disease Severity. Eur. J. Neurol. 2021, 28, 3324–3331. [Google Scholar] [CrossRef] [PubMed]
  106. Sutter, R.; Hert, L.; De Marchis, G.M.; Twerenbold, R.; Kappos, L.; Naegelin, Y.; Kuster, G.M.; Benkert, P.; Jost, J.; Maceski, A.M.; et al. Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. Ann. Neurol. 2021, 89, 610–616. [Google Scholar] [CrossRef]
  107. Verde, F.; Milone, I.; Bulgarelli, I.; Peverelli, S.; Colombrita, C.; Maranzano, A.; Calcagno, N.; Ticozzi, N.; Perego, G.B.; Parati, G.; et al. Serum Neurofilament Light Chain Levels in COVID-19 Patients without Major Neurological Manifestations. J. Neurol. 2022, 269, 5691–5701. [Google Scholar] [CrossRef]
  108. Kanberg, N.; Ashton, N.J.; Andersson, L.-M.; Yilmaz, A.; Lindh, M.; Nilsson, S.; Price, R.W.; Blennow, K.; Zetterberg, H.; Gisslén, M. Neurochemical Evidence of Astrocytic and Neuronal Injury Commonly Found in COVID-19. Neurology 2020, 95, e1754–e1759. [Google Scholar] [CrossRef]
  109. Klein, R.S.; Garber, C.; Howard, N. Infectious Immunity in the Central Nervous System and Brain Function. Nat. Immunol. 2017, 18, 132–141. [Google Scholar] [CrossRef]
  110. Miner, J.J.; Daniels, B.P.; Shrestha, B.; Proenca-Modena, J.L.; Lew, E.D.; Lazear, H.M.; Gorman, M.J.; Lemke, G.; Klein, R.S.; Diamond, M.S. The TAM Receptor Mertk Protects against Neuroinvasive Viral Infection by Maintaining Blood-Brain Barrier Integrity. Nat. Med. 2015, 21, 1464–1472. [Google Scholar] [CrossRef]
  111. Barichello, T.; Generoso, J.; Simoes, L.; Sharin, V.; Ceretta, R.; Dominguini, D.; Comim, C.; Vilela, M.; Teixeira, A.; Quevedo, J. Interleukin-1β Receptor Antagonism Prevents Cognitive Impairment Following Experimental Bacterial Meningitis. Curr. Neurovasc. Res. 2015, 12, 253–261. [Google Scholar] [CrossRef]
  112. Filiano, A.J.; Xu, Y.; Tustison, N.J.; Marsh, R.L.; Baker, W.; Smirnov, I.; Overall, C.C.; Gadani, S.P.; Turner, S.D.; Weng, Z.; et al. Unexpected Role of Interferon-γ in Regulating Neuronal Connectivity and Social Behaviour. Nature 2016, 535, 425–429. [Google Scholar] [CrossRef]
  113. Derecki, N.C.; Cardani, A.N.; Yang, C.H.; Quinnies, K.M.; Crihfield, A.; Lynch, K.R.; Kipnis, J. Regulation of Learning and Memory by Meningeal Immunity: A Key Role for IL-4. J. Exp. Med. 2010, 207, 1067–1080. [Google Scholar] [CrossRef]
  114. Garber, C.; Soung, A.; Vollmer, L.L.; Kanmogne, M.; Last, A.; Brown, J.; Klein, R.S. T Cells Promote Microglia-Mediated Synaptic Elimination and Cognitive Dysfunction during Recovery from Neuropathogenic Flaviviruses. Nat. Neurosci. 2019, 22, 1276–1288. [Google Scholar] [CrossRef]
  115. Vanamee, É.S.; Faustman, D.L. Structural Principles of Tumor Necrosis Factor Superfamily Signaling. Sci. Signal 2018, 11, eaao4910. [Google Scholar] [CrossRef]
  116. del Rey, A.; Balschun, D.; Wetzel, W.; Randolf, A.; Besedovsky, H.O. A Cytokine Network Involving Brain-Borne IL-1β, IL-1ra, IL-18, IL-6, and TNFα Operates during Long-Term Potentiation and Learning. Brain Behav. Immun. 2013, 33, 15–23. [Google Scholar] [CrossRef]
  117. Pettigrew, L.C.; Kryscio, R.J.; Norris, C.M. The TNFα-Transgenic Rat: Hippocampal Synaptic Integrity, Cognition, Function, and Post-Ischemic Cell Loss. PLoS ONE 2016, 11, e0154721. [Google Scholar] [CrossRef]
  118. Chen, Z.; Palmer, T.D. Differential Roles of TNFR1 and TNFR2 Signaling in Adult Hippocampal Neurogenesis. Brain Behav. Immun. 2013, 30, 45–53. [Google Scholar] [CrossRef]
  119. Prajapati, P.; Sripada, L.; Singh, K.; Bhatelia, K.; Singh, R.; Singh, R. TNF-α Regulates MiRNA Targeting Mitochondrial Complex-I and Induces Cell Death in Dopaminergic Cells. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 2015, 1852, 451–461. [Google Scholar] [CrossRef]
  120. Rothaug, M.; Becker-Pauly, C.; Rose-John, S. The Role of Interleukin-6 Signaling in Nervous Tissue. Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 2016, 1863, 1218–1227. [Google Scholar] [CrossRef]
  121. Liu, Z.; Guan, Y.; Sun, X.; Shi, L.; Liang, R.; Lv, X.; Xin, W. HSV-1 Activates NF-KappaB in Mouse Astrocytes and Increases TNF-Alpha and IL-6 Expression via Toll-like Receptor 3. Neurol. Res. 2013, 35, 755–762. [Google Scholar] [CrossRef]
  122. Rubin, E.J.; Longo, D.L.; Baden, L.R. Interleukin-6 Receptor Inhibition in COVID-19—Cooling the Inflammatory Soup. N. Engl. J. Med. 2021, 384, 1564–1565. [Google Scholar] [CrossRef]
  123. Lefèvre, C.; Plocque, A.; Tran, M.; Creux, M.; Philippart, F. Inhibiteurs Du Récepteur de l’IL-6 Dans Le Traitement de La COVID-19: Que Savons-Nous ? Rev. Mal. Respir. 2023, 40, 24–37. [Google Scholar] [CrossRef] [PubMed]
  124. Santa Cruz, A.; Mendes-Frias, A.; Oliveira, A.I.; Dias, L.; Matos, A.R.; Carvalho, A.; Capela, C.; Pedrosa, J.; Castro, A.G.; Silvestre, R. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. Front. Immunol. 2021, 12, 613422. [Google Scholar] [CrossRef]
  125. Ghofrani Nezhad, M.; Jami, G.; Kooshkaki, O.; Chamani, S.; Naghizadeh, A. The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical). J. Interferon Cytokine Res. 2023, 43, 147–163. [Google Scholar] [CrossRef]
  126. Avila-Nava, A.; Cortes-Telles, A.; Torres-Erazo, D.; López-Romero, S.; Chim Aké, R.; Gutiérrez Solis, A.L. Serum IL-6: A Potential Biomarker of Mortality among SARS-CoV-2 Infected Patients in Mexico. Cytokine 2021, 143, 155543. [Google Scholar] [CrossRef] [PubMed]
  127. Wu, Y.; Na, X.; Zang, Y.; Cui, Y.; Xin, W.; Pang, R.; Zhou, L.; Wei, X.; Li, Y.; Liu, X. Upregulation of Tumor Necrosis Factor-Alpha in Nucleus Accumbens Attenuates Morphine-Induced Rewarding in a Neuropathic Pain Model. Biochem. Biophys. Res. Commun. 2014, 449, 502–507. [Google Scholar] [CrossRef] [PubMed]
  128. Stellwagen, D.; Malenka, R.C. Synaptic Scaling Mediated by Glial TNF-α. Nature 2006, 440, 1054–1059. [Google Scholar] [CrossRef]
  129. Wall, A.M.; Mukandala, G.; Greig, N.H.; O’Connor, J.J. Tumor Necrosis Factor-α Potentiates Long-term Potentiation in the Rat Dentate Gyrus after Acute Hypoxia. J. Neurosci. Res. 2015, 93, 815–829. [Google Scholar] [CrossRef]
  130. Habbas, S.; Santello, M.; Becker, D.; Stubbe, H.; Zappia, G.; Liaudet, N.; Klaus, F.R.; Kollias, G.; Fontana, A.; Pryce, C.R.; et al. Neuroinflammatory TNFα Impairs Memory via Astrocyte Signaling. Cell 2015, 163, 1730–1741. [Google Scholar] [CrossRef]
  131. Chien, C.-H.; Lee, M.-J.; Liou, H.-C.; Liou, H.-H.; Fu, W.-M. Microglia-Derived Cytokines/Chemokines Are Involved in the Enhancement of LPS-Induced Loss of Nigrostriatal Dopaminergic Neurons in DJ-1 Knockout Mice. PLoS ONE 2016, 11, e0151569. [Google Scholar] [CrossRef]
  132. Vlkolinský, R.; Siggins, G.R.; Campbell, I.L.; Krucker, T. Acute Exposure to CXC Chemokine Ligand 10, but Not Its Chronic Astroglial Production, Alters Synaptic Plasticity in Mouse Hippocampal Slices. J. Neuroimmunol. 2004, 150, 37–47. [Google Scholar] [CrossRef]
  133. Li, L.; Walker, T.L.; Zhang, Y.; Mackay, E.W.; Bartlett, P.F. Endogenous Interferon Directly Regulates Neural Precursors in the Non-Inflammatory Brain. J. Neurosci. 2010, 30, 9038–9050. [Google Scholar] [CrossRef]
  134. Corbin, J.G.; Kelly, D.; Rath, E.M.; Baerwald, K.D.; Suzuki, K.; Popko, B. Targeted CNS Expression of Interferon-γ in Transgenic Mice Leads to Hypomyelination, Reactive Gliosis, and Abnormal Cerebellar Development. Mol. Cell. Neurosci. 1996, 7, 354–370. [Google Scholar] [CrossRef] [PubMed]
  135. Cutando, L.; Busquets-Garcia, A.; Puighermanal, E.; Gomis-González, M.; Delgado-García, J.M.; Gruart, A.; Maldonado, R.; Ozaita, A. Microglial Activation Underlies Cerebellar Deficits Produced by Repeated Cannabis Exposure. J. Clin. Investig. 2013, 123, 2816–2831. [Google Scholar] [CrossRef] [PubMed]
  136. Stojakovic, A.; Paz-Filho, G.; Arcos-Burgos, M.; Licinio, J.; Wong, M.-L.; Mastronardi, C.A. Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement. Mol. Neurobiol. 2017, 54, 4486–4495. [Google Scholar] [CrossRef]
  137. Majolo, F.; Silva, G.L.d.; Vieira, L.; Anli, C.; Timmers, L.F.S.M.; Laufer, S.; Goettert, M.I. Neuropsychiatric Disorders and COVID-19: What We Know So Far. Pharmaceuticals 2021, 14, 933. [Google Scholar] [CrossRef]
  138. Liotta, E.M.; Batra, A.; Clark, J.R.; Shlobin, N.A.; Hoffman, S.C.; Orban, Z.S.; Koralnik, I.J. Frequent Neurologic Manifestations and Encephalopathy-Associated Morbidity in COVID-19 Patients. Ann. Clin. Transl. Neurol. 2020, 7, 2221–2230. [Google Scholar] [CrossRef]
  139. Nersesjan, V.; Christensen, R.H.B.; Andersen, E.W.; Kondziella, D.; Benros, M.E. Antipsychotic Exposure and Infection Risk in People with Schizophrenia Spectrum Disorders during the COVID-19 Pandemic: A Danish Nationwide Registry Study. Lancet Psychiatry 2024, 11, 796–806. [Google Scholar] [CrossRef]
  140. Baranova, A.; Cao, H.; Zhang, F. Severe COVID-19 Increases the Risk of Schizophrenia. Psychiatry Res. 2022, 317, 114809. [Google Scholar] [CrossRef] [PubMed]
  141. Merzon, E.; Weiss, M.D.; Cortese, S.; Rotem, A.; Schneider, T.; Craig, S.G.; Vinker, S.; Golan Cohen, A.; Green, I.; Ashkenazi, S.; et al. The Association between ADHD and the Severity of COVID-19 Infection. J. Atten. Disord. 2022, 26, 491–501. [Google Scholar] [CrossRef]
  142. Liu, N.; Tan, J.-S.; Liu, L.; Wang, Y.; Hua, L.; Qian, Q. Genetic Predisposition Between COVID-19 and Four Mental Illnesses: A Bidirectional, Two-Sample Mendelian Randomization Study. Front. Psychiatry 2021, 12, 746276. [Google Scholar] [CrossRef]
  143. Jyonouchi, H.; Geng, L.; Rossignol, D.A.; Frye, R.E. Long COVID Syndrome Presenting as Neuropsychiatric Exacerbations in Autism Spectrum Disorder: Insights for Treatment. J. Pers. Med. 2022, 12, 1815. [Google Scholar] [CrossRef] [PubMed]
  144. Aslan Genç, H.; Doenyas, C.; Aksu, Y.; Musaoğlu, M.N.; Uzunay, S.; Mutluer, T. Long-Term Behavioral Consequences of the COVID-19 Pandemic for Autistic Individuals and Their Mothers. J. Autism Dev. Disord. 2024, 54, 2578–2590. [Google Scholar] [CrossRef]
  145. Mahase, E. COVID-19: One in Three Has Neurological or Psychiatric Condition Diagnosed after COVID Infection, Study Finds. BMJ 2021, 373, n908. [Google Scholar] [CrossRef] [PubMed]
  146. Paterson, R.W.; Brown, R.L.; Benjamin, L.; Nortley, R.; Wiethoff, S.; Bharucha, T.; Jayaseelan, D.L.; Kumar, G.; Raftopoulos, R.E.; Zambreanu, L.; et al. The Emerging Spectrum of COVID-19 Neurology: Clinical, Radiological and Laboratory Findings. Brain 2020, 143, 3104–3120. [Google Scholar] [CrossRef] [PubMed]
  147. Zarletti, G.; Tiberi, M.; De Molfetta, V.; Bossù, M.; Toppi, E.; Bossù, P.; Scapigliati, G. A Cell-Based ELISA to Improve the Serological Analysis of Anti-SARS-CoV-2 IgG. Viruses 2020, 12, 1274. [Google Scholar] [CrossRef]
  148. Alexopoulos, H.; Magira, E.; Bitzogli, K.; Kafasi, N.; Vlachoyiannopoulos, P.; Tzioufas, A.; Kotanidou, A.; Dalakas, M.C. Anti–SARS-CoV-2 Antibodies in the CSF, Blood-Brain Barrier Dysfunction, and Neurological Outcome. Neurol. Neuroimmunol. Neuroinflamm. 2020, 7, 1–4. [Google Scholar] [CrossRef]
  149. Herrmann, B.L. Die Prävalenz von SARS-CoV-2-IgG-AK Liegt Bei 1.2%. MMW Fortschr. Med. 2020, 162, 44–46. [Google Scholar] [CrossRef]
  150. Galea, I. The Blood–Brain Barrier in Systemic Infection and Inflammation. Cell Mol. Immunol. 2021, 18, 2489–2501. [Google Scholar] [CrossRef] [PubMed]
  151. Espíndola, O.d.M.; Siqueira, M.; Soares, C.N.; Lima, M.A.S.D.d.; Leite, A.C.C.B.; Araujo, A.Q.C.; Brandão, C.O.; Silva, M.T.T. Patients with COVID-19 and Neurological Manifestations Show Undetectable SARS-CoV-2 RNA Levels in the Cerebrospinal Fluid. Int. J. Infect. Dis. 2020, 96, 567–569. [Google Scholar] [CrossRef]
  152. Thakur, K.T.; Miller, E.H.; Glendinning, M.D.; Al-Dalahmah, O.; Banu, M.A.; Boehme, A.K.; Boubour, A.L.; Bruce, S.S.; Chong, A.M.; Claassen, J.; et al. COVID-19 Neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain 2021, 144, 2696–2708. [Google Scholar] [CrossRef]
  153. Yang, A.C.; Kern, F.; Losada, P.M.; Agam, M.R.; Maat, C.A.; Schmartz, G.P.; Fehlmann, T.; Stein, J.A.; Schaum, N.; Lee, D.P.; et al. Dysregulation of Brain and Choroid Plexus Cell Types in Severe COVID-19. Nature 2021, 595, 565–571. [Google Scholar] [CrossRef]
  154. Lee, M.-H.; Perl, D.P.; Nair, G.; Li, W.; Maric, D.; Murray, H.; Dodd, S.J.; Koretsky, A.P.; Watts, J.A.; Cheung, V.; et al. Microvascular Injury in the Brains of Patients with COVID-19. N. Engl. J. Med. 2021, 384, 481–483. [Google Scholar] [CrossRef] [PubMed]
  155. Buzhdygan, T.P.; DeOre, B.J.; Baldwin-Leclair, A.; Bullock, T.A.; McGary, H.M.; Khan, J.A.; Razmpour, R.; Hale, J.F.; Galie, P.A.; Potula, R.; et al. The SARS-CoV-2 Spike Protein Alters Barrier Function in 2D Static and 3D Microfluidic in-Vitro Models of the Human Blood–Brain Barrier. Neurobiol. Dis. 2020, 146, 105131. [Google Scholar] [CrossRef] [PubMed]
  156. Lersy, F.; Benotmane, I.; Helms, J.; Collange, O.; Schenck, M.; Brisset, J.-C.; Chammas, A.; Willaume, T.; Lefebvre, N.; Solis, M.; et al. Cerebrospinal Fluid Features in Patients with Coronavirus Disease 2019 and Neurological Manifestations: Correlation with Brain Magnetic Resonance Imaging Findings in 58 Patients. J. Infect. Dis. 2021, 223, 600–609. [Google Scholar] [CrossRef] [PubMed]
  157. Jarius, S.; Pache, F.; Körtvelyessy, P.; Jelčić, I.; Stettner, M.; Franciotta, D.; Keller, E.; Neumann, B.; Ringelstein, M.; Senel, M.; et al. Cerebrospinal Fluid Findings in COVID-19: A Multicenter Study of 150 Lumbar Punctures in 127 Patients. J. Neuroinflamm. 2022, 19, 19. [Google Scholar] [CrossRef]
  158. Olajide, O.A.; Iwuanyanwu, V.U.; Lepiarz-Raba, I.; Al-Hindawi, A.A. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone. Inflammation 2021, 44, 1865–1877. [Google Scholar] [CrossRef] [PubMed]
  159. Olajide, O.A.; Iwuanyanwu, V.U.; Adegbola, O.D.; Al-Hindawi, A.A. SARS-CoV-2 Spike Glycoprotein S1 Induces Neuroinflammation in BV-2 Microglia. Mol. Neurobiol. 2022, 59, 445–458. [Google Scholar] [CrossRef]
  160. Park, S.H. An Impaired Inflammatory and Innate Immune Response in COVID-19. Mol. Cells 2021, 44, 384–391. [Google Scholar] [CrossRef]
  161. Zhao, Y.; Kuang, M.; Li, J.; Zhu, L.; Jia, Z.; Guo, X.; Hu, Y.; Kong, J.; Yin, H.; Wang, X.; et al. SARS-CoV-2 Spike Protein Interacts with and Activates TLR41. Cell Res. 2021, 31, 818–820. [Google Scholar] [CrossRef]
  162. Shirato, K.; Kizaki, T. SARS-CoV-2 Spike Protein S1 Subunit Induces pro-Inflammatory Responses via Toll-like Receptor 4 Signaling in Murine and Human Macrophages. Heliyon 2021, 7, e06187. [Google Scholar] [CrossRef]
  163. Kircheis, R. In Silico Analyses Indicate a Lower Potency for Dimerization of TLR4/MD-2 as the Reason for the Lower Pathogenicity of Omicron Compared to Wild-Type Virus and Earlier SARS-CoV-2 Variants. Int. J. Mol. Sci. 2024, 25, 5451. [Google Scholar] [CrossRef]
  164. Bocquet-Garçon, A. Impacts of the SARS-CoV-2 Spike Protein on the Innate Immune System: A Review. Cureus 2024, 16, e57008. [Google Scholar] [CrossRef] [PubMed]
  165. Zheng, M.; Karki, R.; Williams, E.P.; Yang, D.; Fitzpatrick, E.; Vogel, P.; Jonsson, C.B.; Kanneganti, T.-D. TLR2 Senses the SARS-CoV-2 Envelope Protein to Produce Inflammatory Cytokines. Nat. Immunol. 2021, 22, 829–838. [Google Scholar] [CrossRef] [PubMed]
  166. Khan, S.; Shafiei, M.S.; Longoria, C.; Schoggins, J.W.; Savani, R.C.; Zaki, H. SARS-CoV-2 Spike Protein Induces Inflammation via TLR2-Dependent Activation of the NF-ΚB Pathway. eLife 2021, 10, e68563. [Google Scholar] [CrossRef] [PubMed]
  167. Nalleballe, K.; Reddy Onteddu, S.; Sharma, R.; Dandu, V.; Brown, A.; Jasti, M.; Yadala, S.; Veerapaneni, K.; Siddamreddy, S.; Avula, A.; et al. Spectrum of Neuropsychiatric Manifestations in COVID-19. Brain Behav. Immun. 2020, 88, 71–74. [Google Scholar] [CrossRef]
  168. Varatharaj, A.; Thomas, N.; Ellul, M.A.; Davies, N.W.S.; Pollak, T.A.; Tenorio, E.L.; Sultan, M.; Easton, A.; Breen, G.; Zandi, M.; et al. Neurological and Neuropsychiatric Complications of COVID-19 in 153 Patients: A UK-Wide Surveillance Study. Lancet Psychiatry 2020, 7, 875–882. [Google Scholar] [CrossRef]
  169. Ross Russell, A.L.; Hardwick, M.; Jeyanantham, A.; White, L.M.; Deb, S.; Burnside, G.; Joy, H.M.; Smith, C.J.; Pollak, T.A.; Nicholson, T.R.; et al. Spectrum, Risk Factors and Outcomes of Neurological and Psychiatric Complications of COVID-19: A UK-Wide Cross-Sectional Surveillance Study. Brain Commun. 2021, 3, fcab168. [Google Scholar] [CrossRef]
  170. Losee, S.; Hanson, H. COVID-19 Delirium with Psychosis: A Case Report. S. D. Med. 2020, 73. [Google Scholar]
  171. Beach, S.R.; Praschan, N.C.; Hogan, C.; Dotson, S.; Merideth, F.; Kontos, N.; Fricchione, G.L.; Smith, F.A. Delirium in COVID-19: A Case Series and Exploration of Potential Mechanisms for Central Nervous System Involvement. Gen. Hosp. Psychiatry 2020, 65, 47–53. [Google Scholar] [CrossRef]
  172. Baig, A.M.; Khaleeq, A.; Ali, U.; Syeda, H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem. Neurosci. 2020, 11, 995–998. [Google Scholar] [CrossRef]
  173. Sadowski, J.; Klaudel, T.; Rombel-Bryzek, A.; Bułdak, R. Cognitive Dysfunctions in the Course of SARS-CoV-2 Virus Infection, Including NeuroCOVID, Frontal Syndrome and Cytokine Storm (Review). Biomed. Rep. 2024, 21, 103. [Google Scholar] [CrossRef] [PubMed]
  174. Moein, S.T.; Hashemian, S.M.R.; Mansourafshar, B.; Khorram-Tousi, A.; Tabarsi, P.; Doty, R.L. Smell Dysfunction: A Biomarker for COVID-19. Int. Forum Allergy Rhinol. 2020, 10, 944–950. [Google Scholar] [CrossRef] [PubMed]
  175. Chee, J.; Chern, B.; Loh, W.S.; Mullol, J.; Wang, D.Y. Pathophysiology of SARS-CoV-2 Infection of Nasal Respiratory and Olfactory Epithelia and Its Clinical Impact. Curr. Allergy Asthma Rep. 2023, 23, 121–131. [Google Scholar] [CrossRef]
  176. Ahn, J.H.; Kim, J.; Hong, S.P.; Choi, S.Y.; Yang, M.J.; Ju, Y.S.; Kim, Y.T.; Kim, H.M.; Rahman, M.T.; Chung, M.K.; et al. Nasal Ciliated Cells Are Primary Targets for SARS-CoV-2 Replication in the Early Stage of COVID-19. J. Clin. Investig. 2021, 131, e148517. [Google Scholar] [CrossRef] [PubMed]
  177. Xu, H.; Zhong, L.; Deng, J.; Peng, J.; Dan, H.; Zeng, X.; Li, T.; Chen, Q. High Expression of ACE2 Receptor of 2019-NCoV on the Epithelial Cells of Oral Mucosa. Int. J. Oral Sci. 2020, 12, 1–5. [Google Scholar] [CrossRef]
  178. Sakaguchi, W.; Kubota, N.; Shimizu, T.; Saruta, J.; Fuchida, S.; Kawata, A.; Yamamoto, Y.; Sugimoto, M.; Yakeishi, M.; Tsukinoki, K. Existence of SARS-CoV-2 Entry Molecules in the Oral Cavity. Int. J. Mol. Sci. 2020, 21, 6000. [Google Scholar] [CrossRef]
  179. Fu, J.; Zhou, B.; Zhang, L.; Balaji, K.S.; Wei, C.; Liu, X.; Chen, H.; Peng, J.; Fu, J. Expressions and Significances of the Angiotensin-Converting Enzyme 2 Gene, the Receptor of SARS-CoV-2 for COVID-19. Mol. Biol. Rep. 2020, 47, 4383–4392. [Google Scholar] [CrossRef] [PubMed]
  180. Li, Y.C.; Bai, W.Z.; Hashikawa, T. The Neuroinvasive Potential of SARS-CoV2 May Play a Role in the Respiratory Failure of COVID-19 Patients. J. Med. Virol. 2020, 92, 552–555. [Google Scholar] [CrossRef]
  181. Pilotto, A.; Odolini, S.; Masciocchi, S.; Comelli, A.; Volonghi, I.; Gazzina, S.; Nocivelli, S.; Pezzini, A.; Focà, E.; Caruso, A.; et al. Steroid-Responsive Encephalitis in Coronavirus Disease 2019. Ann. Neurol. 2020, 88, 423–427. [Google Scholar] [CrossRef]
  182. Ismail, I.I.; Salama, S. Association of CNS Demyelination and COVID-19 Infection: An Updated Systematic Review. J. Neurol. 2022, 269, 541–576. [Google Scholar] [CrossRef]
  183. Ismail, I.I.; Salama, S. A Systematic Review of Cases of CNS Demyelination Following COVID-19 Vaccination. J. Neuroimmunol. 2022, 362, 577765. [Google Scholar] [CrossRef]
  184. Bauer, L.; Laksono, B.M.; de Vrij, F.M.S.; Kushner, S.A.; Harschnitz, O.; van Riel, D. The Neuroinvasiveness, Neurotropism, and Neurovirulence of SARS-CoV-2. Trends Neurosci. 2022, 45, 358–368. [Google Scholar] [CrossRef] [PubMed]
  185. Fairweather, D.L.; Frisancho-Kiss, S.; Rose, N.R. Viruses as Adjuvants for Autoimmunity: Evidence from Coxsackievirus-Induced Myocarditis. Rev. Med. Virol. 2005, 15, 17–27. [Google Scholar] [CrossRef] [PubMed]
  186. Zhao, H.; Shen, D.; Zhou, H.; Liu, J.; Chen, S. Guillain-Barré Syndrome Associated with SARS-CoV-2 Infection: Causality or Coincidence? Lancet Neurol. 2020, 19, 383–384. [Google Scholar] [CrossRef]
  187. Garg, R.K.; Paliwal, V.K.; Gupta, A. Encephalopathy in Patients with COVID-19: A Review. J. Med. Virol. 2021, 93, 206–222. [Google Scholar] [CrossRef]
  188. Shah, P.; Patel, J.; Soror, N.N.; Kartan, R. Encephalopathy in COVID-19 Patients. Cureus 2021, 13, e16620. [Google Scholar] [CrossRef]
  189. Lin, J.; Zheng, D.; Tian, D.; Zheng, P.; Zhang, H.; Li, C.; Lei, C.; Shi, F.; Wang, H. High Frequency of Autoantibodies in COVID-19 Patients with Central Nervous System Complications: A Multicenter Observational Study. Mol. Neurobiol. 2024, 61, 8414–8424. [Google Scholar] [CrossRef]
  190. Abenza Abildúa, M.J.; Atienza, S.; Carvalho Monteiro, G.; Erro Aguirre, M.E.; Imaz Aguayo, L.; Freire Álvarez, E.; García-Azorín, D.; Gil-Olarte Montesinos, I.; Lara Lezama, L.B.; Navarro Pérez, M.P.; et al. Encefalopatías y Encefalitis Durante La Infección Aguda Por SARS-CoV2. Registro de La Sociedad Española de Neurología SEN COVID-19. Neurología 2021, 36, 127–134. [Google Scholar] [CrossRef] [PubMed]
  191. Frontera, J.A.; Melmed, K.; Fang, T.; Granger, A.; Lin, J.; Yaghi, S.; Zhou, T.; Lewis, A.; Kurz, S.; Kahn, D.E.; et al. Toxic Metabolic Encephalopathy in Hospitalized Patients with COVID-19. Neurocrit Care 2021, 35, 693–706. [Google Scholar] [CrossRef]
  192. Poyiadji, N.; Shahin, G.; Noujaim, D.; Stone, M.; Patel, S.; Griffith, B. COVID-19–Associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. Radiology 2020, 296, E119–E120. [Google Scholar] [CrossRef]
  193. Rossi, A. Imaging of Acute Disseminated Encephalomyelitis. Neuroimaging Clin. N. Am. 2008, 18, 149–161. [Google Scholar] [CrossRef] [PubMed]
  194. Waldrop, G.; Safavynia, S.A.; Barra, M.E.; Agarwal, S.; Berlin, D.A.; Boehme, A.K.; Brodie, D.; Choi, J.M.; Doyle, K.; Fins, J.J.; et al. Prolonged Unconsciousness Is Common in COVID-19 and Associated with Hypoxemia. Ann. Neurol. 2022, 91, 740–755. [Google Scholar] [CrossRef]
  195. Liu, N.; Zhang, F.; Wei, C.; Jia, Y.; Shang, Z.; Sun, L.; Wu, L.; Sun, Z.; Zhou, Y.; Wang, Y.; et al. Prevalence and Predictors of PTSS during COVID-19 Outbreak in China Hardest-Hit Areas: Gender Differences Matter. Psychiatry Res. 2020, 287, 112921. [Google Scholar] [CrossRef]
  196. Maamar, M.; Artime, A.; Pariente, E.; Fierro, P.; Ruiz, Y.; Gutiérrez, S.; Tobalina, M.; Díaz-Salazar, S.; Ramos, C.; Olmos, J.M.; et al. Post-COVID-19 Syndrome, Low-Grade Inflammation and Inflammatory Markers: A Cross-Sectional Study. Curr. Med. Res. Opin. 2022, 38, 901–909. [Google Scholar] [CrossRef]
  197. National Academies of Sciences, Engineering, and Medicine. Long-Term Health Effects of COVID-19; Volberding, P.A., Chu, B.X., Spicer, C.M., Eds.; National Academies Press: Washington, DC, USA, 2024; ISBN 978-0-309-71860-8. [Google Scholar]
  198. Serrano-Castro, P.J.; Estivill-Torrús, G.; Cabezudo-García, P.; Reyes-Bueno, J.A.; Ciano Petersen, N.; Aguilar-Castillo, M.J.; Suárez-Pérez, J.; Jiménez-Hernández, M.D.; Moya-Molina, M.Á.; Oliver-Martos, B.; et al. Impact of SARS-CoV-2 Infection on Neurodegenerative and Neuropsychiatric Diseases: A Delayed Pandemic? Neurología 2020, 35, 245–251. [Google Scholar] [CrossRef] [PubMed]
  199. Kubota, T.; Kuroda, N.; Sone, D. Neuropsychiatric Aspects of Long COVID: A Comprehensive Review. Psychiatry Clin. Neurosci. 2023, 77, 84–93. [Google Scholar] [CrossRef] [PubMed]
  200. Bo, H.X.; Li, W.; Yang, Y.; Wang, Y.; Zhang, Q.; Cheung, T.; Wu, X.; Xiang, Y.T. Posttraumatic Stress Symptoms and Attitude toward Crisis Mental Health Services among Clinically Stable Patients with COVID-19 in China. Psychol. Med. 2021, 51, 1052–1053. [Google Scholar] [CrossRef]
  201. Lam, M.H.B.; Wing, Y.K.; Yu, M.W.M.; Leung, C.M.; Ma, R.C.W.; Kong, A.P.S.; So, W.Y.; Fong, S.Y.Y.; Lam, S.P. Mental Morbidities and Chronic Fatigue in Severe Acute Respiratory Syndrome Survivors Long-Term Follow-Up. Arch. Intern. Med. 2009, 169, 2142–2147. [Google Scholar] [CrossRef]
  202. Graham, E.L.; Clark, J.R.; Orban, Z.S.; Lim, P.H.; Szymanski, A.L.; Taylor, C.; DiBiase, R.M.; Jia, D.T.; Balabanov, R.; Ho, S.U.; et al. Persistent Neurologic Symptoms and Cognitive Dysfunction in Non-Hospitalized COVID-19 “Long Haulers”. Ann. Clin. Transl. Neurol. 2021, 8, 1073–1085. [Google Scholar] [CrossRef]
  203. Taquet, M.; Sillett, R.; Zhu, L.; Mendel, J.; Camplisson, I.; Dercon, Q.; Harrison, P.J. Neurological and Psychiatric Risk Trajectories after SARS-CoV-2 Infection: An Analysis of 2-Year Retrospective Cohort Studies Including 1 284 437 Patients. Lancet Psychiatry 2022, 9, 815–827. [Google Scholar] [CrossRef]
  204. Behnood, S.A.; Shafran, R.; Bennett, S.D.; Zhang, A.X.D.; O’Mahoney, L.L.; Stephenson, T.J.; Ladhani, S.N.; De Stavola, B.L.; Viner, R.M.; Swann, O.V. Persistent Symptoms Following SARS-CoV-2 Infection amongst Children and Young People: A Meta-Analysis of Controlled and Uncontrolled Studies. J. Infect. 2022, 84, 158–170. [Google Scholar] [CrossRef] [PubMed]
  205. Zheng, Y.-B.; Zeng, N.; Yuan, K.; Tian, S.-S.; Yang, Y.-B.; Gao, N.; Chen, X.; Zhang, A.-Y.; Kondratiuk, A.L.; Shi, P.-P.; et al. Prevalence and Risk Factor for Long COVID in Children and Adolescents: A Meta-Analysis and Systematic Review. J. Infect. Public. Health 2023, 16, 660–672. [Google Scholar] [CrossRef] [PubMed]
  206. Abdelhak, A.; Huss, A.; Kassubek, J.; Tumani, H.; Otto, M. Serum GFAP as a Biomarker for Disease Severity in Multiple Sclerosis. Sci. Rep. 2018, 8, 14798. [Google Scholar] [CrossRef] [PubMed]
  207. Watanabe, M.; Nakamura, Y.; Michalak, Z.; Isobe, N.; Barro, C.; Leppert, D.; Matsushita, T.; Hayashi, F.; Yamasaki, R.; Kuhle, J.; et al. Serum GFAP and Neurofilament Light as Biomarkers of Disease Activity and Disability in NMOSD. Neurology 2019, 93, E1299–E1311. [Google Scholar] [CrossRef] [PubMed]
  208. Huang, Z.; Haile, K.; Gedefaw, L.; Lau, B.W.-M.; Jin, L.; Yip, S.P.; Huang, C.-L. Blood Biomarkers as Prognostic Indicators for Neurological Injury in COVID-19 Patients: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci. 2023, 24, 15738. [Google Scholar] [CrossRef]
  209. Aamodt, A.H.; Høgestøl, E.A.; Popperud, T.H.; Holter, J.C.; Dyrhol-Riise, A.M.; Tonby, K.; Stiksrud, B.; Quist-Paulsen, E.; Berge, T.; Barratt-Due, A.; et al. Blood Neurofilament Light Concentration at Admittance: A Potential Prognostic Marker in COVID-19. J. Neurol. 2021, 268, 3574–3583. [Google Scholar] [CrossRef]
  210. Ameres, M.; Brandstetter, S.; Toncheva, A.A.; Kabesch, M.; Leppert, D.; Kuhle, J.; Wellmann, S. Association of Neuronal Injury Blood Marker Neurofilament Light Chain with Mild-to-Moderate COVID-19. J. Neurol. 2020, 267, 3476–3478. [Google Scholar] [CrossRef]
  211. Cooper, J.; Stukas, S.; Hoiland, R.L.; Fergusson, N.A.; Thiara, S.; Foster, D.; Mitra, A.; Stoessl, J.A.; Panenka, W.J.; Sekhon, M.S.; et al. Quantification of Neurological Blood-Based Biomarkers in Critically Ill Patients with Coronavirus Disease 2019. Crit. Care Explor. 2020, 2, E0238. [Google Scholar] [CrossRef]
  212. Salvio, A.L.; Fernandes, R.A.; Ferreira, H.F.A.; Duarte, L.A.; Gutman, E.G.; Raposo-Vedovi, J.V.; Filho, C.H.F.R.; da Costa Nunes Pimentel Coelho, W.L.; Passos, G.F.; Andraus, M.E.C.; et al. High Levels of NfL, GFAP, TAU, and UCH-L1 as Potential Predictor Biomarkers of Severity and Lethality in Acute COVID-19. Mol. Neurobiol. 2024, 61, 3545–3558. [Google Scholar] [CrossRef]
  213. Yang, Z.; Xu, H.; Sura, L.; Arja, R.D.; Patterson, R.L.; Rossignol, C.; Albayram, M.; Rajderkar, D.; Ghosh, S.; Wang, K.; et al. Combined GFAP, NFL, Tau, and UCH-L1 Panel Increases Prediction of Outcomes in Neonatal Encephalopathy. Pediatr. Res. 2023, 93, 1199–1207. [Google Scholar] [CrossRef]
  214. Dadkhah, M.; Talei, S.; Doostkamel, D.; Molaei, S.; Rezaei, N. The Impact of COVID-19 on Diagnostic Biomarkers in Neuropsychiatric and Neuroimmunological Diseases: A Review. Rev. Neurosci. 2022, 33, 79–92. [Google Scholar] [CrossRef] [PubMed]
  215. Chmielewska, N.; Szyndler, J.; Makowska, K.; Wojtyna, D.; Maciejak, P.; Płaźnik, A. Looking for Novel, Brain-Derived, Peripheral Biomarkers of Neurological Disorders. Neurol. Neurochir. Pol. 2018, 52, 318–325. [Google Scholar] [CrossRef] [PubMed]
  216. Brunkhorst, R.; Pfeilschifter, W.; Foerch, C. Astroglial Proteins as Diagnostic Markers of Acute Intracerebral Hemorrhage-Pathophysiological Background and Clinical Findings. Transl. Stroke Res. 2010, 1, 246–251. [Google Scholar] [CrossRef]
  217. Sahin, B.E.; Celikbilek, A.; Kocak, Y.; Saltoglu, G.T.; Konar, N.M.; Hizmali, L. Plasma Biomarkers of Brain Injury in COVID-19 Patients with Neurological Symptoms. J. Neurol. Sci. 2022, 439, 120324. [Google Scholar] [CrossRef] [PubMed]
  218. Ladopoulos, T.; Zand, R.; Shahjouei, S.; Chang, J.J.; Motte, J.; Charles James, J.; Katsanos, A.H.; Kerro, A.; Farahmand, G.; Vaghefi Far, A.; et al. COVID-19: Neuroimaging Features of a Pandemic. J. Neuroimaging 2021, 31, 228–243. [Google Scholar] [CrossRef]
  219. El Beltagi, A.H.; Vattoth, S.; Abdelhady, M.; Ahmed, I.; Paksoy, Y.; Abou Kamar, M.; Alsoub, H.; Almaslamani, M.; Alkhal, A.L.; Own, A.; et al. Spectrum of Neuroimaging Findings in COVID-19. Br. J. Radiol. 2021, 94, 20200812. [Google Scholar] [CrossRef]
  220. Safadieh, G.H.; El Majzoub, R.; Abou Abbas, L. Neuroimaging Findings in Children with COVID-19 Infection: A Systematic Review and Meta-Analysis. Sci. Rep. 2024, 14, 4790. [Google Scholar] [CrossRef]
  221. Sarkar, S.; Kaur, T.; Ranjan, P.; Sahu, A.; Kumari, A. Tools for the Evaluation of the Psychological Impact of COVID-19. J. Fam. Med. Prim. Care 2021, 10, 1503–1507. [Google Scholar] [CrossRef]
  222. Taylor, S.; Landry, C.A.; Paluszek, M.M.; Fergus, T.A.; McKay, D.; Asmundson, G.J.G. Development and Initial Validation of the COVID Stress Scales. J. Anxiety Disord. 2020, 72, 102232. [Google Scholar] [CrossRef]
  223. Grundmann, A.; Wu, C.H.; Hardwick, M.; Baillie, J.K.; Openshaw, P.J.M.; Semple, M.G.; Böhning, D.; Pett, S.; Michael, B.D.; Thomas, R.H.; et al. Fewer COVID-19 Neurological Complications with Dexamethasone and Remdesivir. Ann. Neurol. 2023, 93, 88–102. [Google Scholar] [CrossRef]
  224. Brown, R.L.; Benjamin, L.; Lunn, M.P.; Bharucha, T.; Zandi, M.S.; Hoskote, C.; McNamara, P.; Manji, H. Pathophysiology, Diagnosis, and Management of Neuroinflammation in COVID-19. BMJ 2023, 382, e073923. [Google Scholar] [CrossRef] [PubMed]
  225. Taquet, M.; Dercon, Q.; Harrison, P.J. Six-Month Sequelae of Post-Vaccination SARS-CoV-2 Infection: A Retrospective Cohort Study of 10,024 Breakthrough Infections. Brain Behav. Immun. 2022, 103, 154–162. [Google Scholar] [CrossRef] [PubMed]
  226. Harrison, P.J.; Taquet, M. Neuropsychiatric Disorders Following SARS-CoV-2 Infection. Brain 2023, 146, 2241–2247. [Google Scholar] [CrossRef] [PubMed]
  227. Oelsner, E.C.; Sun, Y.; Balte, P.P.; Allen, N.B.; Andrews, H.; Carson, A.; Cole, S.A.; Coresh, J.; Couper, D.; Cushman, M.; et al. Epidemiologic Features of Recovery From SARS-CoV-2 Infection. JAMA Netw. Open 2024, 7, e2417440. [Google Scholar] [CrossRef]
  228. Li, X.; Raventós, B.; Roel, E.; Pistillo, A.; Martinez-Hernandez, E.; Delmestri, A.; Reyes, C.; Strauss, V.; Prieto-Alhambra, D.; Burn, E.; et al. Association between COVID-19 Vaccination, SARS-CoV-2 Infection, and Risk of Immune Mediated Neurological Events: Population Based Cohort and Self-Controlled Case Series Analysis. BMJ 2022, 376, e068373. [Google Scholar] [CrossRef]
  229. Tsampasian, V.; Elghazaly, H.; Chattopadhyay, R.; Debski, M.; Naing, T.K.P.; Garg, P.; Clark, A.; Ntatsaki, E.; Vassiliou, V.S. Risk Factors Associated with Post-COVID-19 Condition A Systematic Review and Meta-Analysis. JAMA Intern. Med. 2023, 183, 566–580. [Google Scholar] [CrossRef]
  230. National Institute for Health and Excellence COVID-19 Rapid Guideline: Managing COVID-19. NICE Guideline 2024. Available online: https://www.nice.org.uk/guidance/ng191/chapter/Update-information (accessed on 20 June 2024).
Viruses 16 01811 g001
Figure 1. Proposed pathways of neuropsychiatric manifestations in SARS-CoV-2 infection.
Figure 1. Proposed pathways of neuropsychiatric manifestations in SARS-CoV-2 infection.
Viruses 16 01811 g001
Viruses 16 01811 g002
Figure 2. The impact of the SARS-CoV-2 infection on the nervous system and the resulting injuries.
Figure 2. The impact of the SARS-CoV-2 infection on the nervous system and the resulting injuries.
Viruses 16 01811 g002
Viruses 16 01811 g004
Figure 4. Neurological manifestations of the SARS-CoV infection described in the literature. ADEM—acute disseminated encephalomyelitis; AHLE—acute hemorrhagic leukoencephalitis; MOGAD—myelin oligodendrocyte glycoprotein antibody-associated disease; PIMS-TS—pediatric inflammatory multisystem syndrome; PRES—posterior reversible encephalopathy syndrome.
Figure 4. Neurological manifestations of the SARS-CoV infection described in the literature. ADEM—acute disseminated encephalomyelitis; AHLE—acute hemorrhagic leukoencephalitis; MOGAD—myelin oligodendrocyte glycoprotein antibody-associated disease; PIMS-TS—pediatric inflammatory multisystem syndrome; PRES—posterior reversible encephalopathy syndrome.
Viruses 16 01811 g004
Viruses 16 01811 g005
Figure 5. Management and diagnostic approaches for neurological sequelae in SARS-CoV-2 infection [224].
Figure 5. Management and diagnostic approaches for neurological sequelae in SARS-CoV-2 infection [224].
Viruses 16 01811 g005
Table 1. Most common acute symptoms of COVID-19 disease.
Table 1. Most common acute symptoms of COVID-19 disease.
Acute Symptoms of COVID-19 DiseasePossible Associated Pathophysiology
Anosmia, AgeusiaNasal congestion, resulting in the loss of fine olfactory receptor cell endings, making them unable to detect odors [172,173,174];
SARS-CoV-2 virus predominantly colonizes the patients’ nasal cavity, triggering inflammation in the olfactory nerves and causing structural damage to the receptors [173,175,176];
High expression of ACE2 receptors in the tongue cells as compared to other mouth tissues makes them more susceptible to viral binding [177,178,179].
Neurogenic respiratory failureSARS-CoV-2 can infect nerve cells in the myelencephalon, which is responsible for regulating several basic functions of the autonomic nervous system, including respiration, cardiac function and vasodilation [180];
Involved secondary mechanism due to increased inflammatory markers like TNFα and IL-8, which have been associated with pleocytosis [181].
GBSGBS may be caused by the neuroinvasion of SARS-CoV-2, causing the side effect of demyelination [18,182,183,184];
The viral infection may trigger an exaggerated immune response via molecular mimicry, which leads to the demyelination of peripheral nerves [185];
First GBS case in a COVID-19 patient reported in January 2020 [186].
EncephalopathyThe most common neurological complication seen in COVID-19 patients from Intensive C [18,187];
Symptoms: restlessness, confusion, delirium [188,189,190];
Can occur in less severe cases, affecting young adults [191];
The first case of acute necrotizing hemorrhagic encephalopathy associated with COVID-19 was reported in 2020 [192];
The base mechanism involves the onset of cytokine storm in the brain, leading to BBB dysfunction [193];
Cases of toxic metabolic encephalopathy were also reported in the literature [191], with risk factors including age, male gender, diabetes, pre-existing conditions [194].
Table 2. Common long COVID-19 symptoms reported in the literature according to the consensus study report 2024 of the National Academies of Sciences, Engineering, and Medicine [197].
Table 2. Common long COVID-19 symptoms reported in the literature according to the consensus study report 2024 of the National Academies of Sciences, Engineering, and Medicine [197].
CategoryLong COVID-19 Symptoms
NeuropsychiatricCognitive dysfunction (brain fog);
Headaches;
Dizziness;
Concentration difficulties;
Memory impairments;
Mood changes;
Tinnitus;
Visual disturbances;
Chronic fatigue syndrome;
Parosmia;
Anosmia;
Sleep disorders;
Anxiety;
Depression;
Fibromyalgia.
RespiratoryShortness of breath;
Chronic cough;
Pulmonary complications;
Breathlessness.
CardiovascularChest pain;
Palpitations;
Tachycardia;
Endothelial dysfunction;
Coagulation disorders.
GastrointestinalNausea;
Diarrhea;
Loss of appetite;
Weight loss;
Gastroesophageal reflux disease;
Irritable bowel syndrome;
Gut dysbiosis.
MusculoskeletalMuscle weakness;
Joint pain;
Musculoskeletal pain.
OtherPost-exertional malaise;
Rash;
Sore throat;
Hair loss;
Pins and needles sensation;
Painful lymph nodes;
Swelling in extremities;
Reduced exercise tolerance;
Bladder control issues;
Sexual dysfunction;
Persistent hiccups;
Endocrine dysfunction;
Kidney dysfunction;
Immune dysregulation;
Mast Cell Activation Syndrome.
Table 3. Non-specific biomarkers used to monitor neurological and psychiatric impairments in COVID-19 disease.
Table 3. Non-specific biomarkers used to monitor neurological and psychiatric impairments in COVID-19 disease.
BiomarkerDescription
Neurological Impairment
NfLNeuronal cytoskeletal protein released into the CSF and blood following neuronal injury or degeneration;
Elevated in COVID-19 patients with neurological complications;
Indicates CNS involvement and progression.
S100B proteinCalcium-binding protein expressed predominantly in astrocytes and oligodendrocytes;
Increased levels indicate glial activation and neuroinflammation;
Reflects severity of neurological complications in COVID-19, including BBB dysfunction.
Other CSF biomarkersIncludes protein levels, cell counts, and inflammatory markers like IL-6, IL-8, TNF-α;
Diagnosis and characterization of neuroinflammatory disorders in COVID-19.
UCH-L1UCH-L1 levels were higher in patients needing ICU transfer;
UCH-L1 linked to neuronal injury.
Psychiatric Impairment
Brain-derived neurotrophic factor (BDFN)Neurotrophin involved in neuronal survival, synaptic plasticity and mood regulation;
Low levels associated with psychiatric symptoms in COVID-19.
Peripheral cytokine profilesElevated cytokine levels, including IL-6, TNFα, and IFN-γ were associated with mood disorders, cognitive impairment, and psychosis in COVID-19 patients.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Pacnejer, A.-M.; Butuca, A.; Dobrea, C.M.; Arseniu, A.M.; Frum, A.; Gligor, F.G.; Arseniu, R.; Vonica, R.C.; Vonica-Tincu, A.L.; Oancea, C.; et al. Neuropsychiatric Burden of SARS-CoV-2: A Review of Its Physiopathology, Underlying Mechanisms, and Management Strategies. Viruses 2024, 16, 1811. https://doi.org/10.3390/v16121811

AMA Style

Pacnejer A-M, Butuca A, Dobrea CM, Arseniu AM, Frum A, Gligor FG, Arseniu R, Vonica RC, Vonica-Tincu AL, Oancea C, et al. Neuropsychiatric Burden of SARS-CoV-2: A Review of Its Physiopathology, Underlying Mechanisms, and Management Strategies. Viruses. 2024; 16(12):1811. https://doi.org/10.3390/v16121811

Chicago/Turabian Style

Pacnejer, Aliteia-Maria, Anca Butuca, Carmen Maximiliana Dobrea, Anca Maria Arseniu, Adina Frum, Felicia Gabriela Gligor, Rares Arseniu, Razvan Constantin Vonica, Andreea Loredana Vonica-Tincu, Cristian Oancea, and et al. 2024. "Neuropsychiatric Burden of SARS-CoV-2: A Review of Its Physiopathology, Underlying Mechanisms, and Management Strategies" Viruses 16, no. 12: 1811. https://doi.org/10.3390/v16121811

APA Style

Pacnejer, A. -M., Butuca, A., Dobrea, C. M., Arseniu, A. M., Frum, A., Gligor, F. G., Arseniu, R., Vonica, R. C., Vonica-Tincu, A. L., Oancea, C., Mogosan, C., Popa Ilie, I. R., Morgovan, C., & Dehelean, C. A. (2024). Neuropsychiatric Burden of SARS-CoV-2: A Review of Its Physiopathology, Underlying Mechanisms, and Management Strategies. Viruses, 16(12), 1811. https://doi.org/10.3390/v16121811

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop